var title_f9_26_9632="Echinococcal liver cyst gross";
var content_f9_26_9632=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Macroscopic appearance of echinococcal cysts in liver tissue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Craig, PS, McManus, DP, Lightlowlers, MW, et al. Prevention and control of cystic echinococcosis. Lancet Infect Dis 2007; 7:385. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_26_9632=[""].join("\n");
var outline_f9_26_9632=null;
var title_f9_26_9633="NSCLC brain met CT";
var content_f9_26_9633=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Brain metastasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Head CT showing one of multiple ring enhancing lesions in the brain of a 45-year-old male presenting with headaches. Biopsies of a right upper lobe mass and subcarinal adenopathy showed adenocarcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_26_9633=[""].join("\n");
var outline_f9_26_9633=null;
var title_f9_26_9634="DiGeorge adult facies";
var content_f9_26_9634=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F52371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F52371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adult patient with 22q11DS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 460px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bassett, AS, Chow, EW, Husted, J, et al. Clinical features of 78 adults with 22q11 Deletion Syndrome. Am J Med Genet A 2005; 138:307. Copyright &copy;2005 John Wiley &amp; Sons, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_26_9634=[""].join("\n");
var outline_f9_26_9634=null;
var title_f9_26_9635="Dialysis or kidney transplantation — which is right for me?";
var content_f9_26_9635=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Dialysis or kidney transplantation ��������� which is right for me? (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?9/26/9635/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/26/9635/contributors\" id=\"au7217\">",
"       Jeffrey S Berns, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?9/26/9635/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/26/9635/contributors\" id=\"se4282\">",
"       Daniel C Brennan, MD, FACP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?9/26/9635/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/26/9635/contributors\" id=\"de1856\">",
"       Alice M Sheridan, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?9/26/9635?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Dialysis and kidney transplantation are treatments for severe kidney failure, also called renal failure, stage 5 chronic kidney disease, and end-stage renal disease. There are two types of dialysis: hemodialysis and peritoneal dialysis.",
"    </p>",
"    <p>",
"     When the kidneys are no longer working effectively, waste products and fluid build up in the blood. Dialysis takes over a portion of the function of the failing kidneys to remove the fluid and waste. Kidney transplantation can completely take over the function of the failing kidneys.",
"    </p>",
"    <p>",
"     This article discusses these therapies, including the advantages, disadvantages, and care required for kidney transplantation and dialysis. You and your family should discuss all of the options with your healthcare provider to make an informed decision.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHEN WILL DIALYSIS OR KIDNEY TRANSPLANTATION BE NEEDED?",
"     </span>",
"    </p>",
"    <p>",
"     Early in the course of kidney disease, medications are used to help preserve kidney function and delay the need for dialysis or transplantation. These early treatments are directed at the underlying kidney disease, secondary factors (such as hypertension) that promote kidney disease progression, and the complications of chronic kidney disease.",
"    </p>",
"    <p>",
"     As the kidneys lose their ability to function, fluid and waste products begin to build up in the blood. Dialysis should begin before kidney disease has advanced to the point where life-threatening complications occur. This usually takes many months or years after kidney disease is first discovered, although sometimes severe kidney failure is discovered for the first time in people who were not previously known to have kidney disease. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"      \"Patient information: Chronic kidney disease (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     It is best to begin dialysis treatments when you have advanced kidney disease, but while you still feel well. You and your doctor will decide when to begin dialysis after considering a number of factors, including your kidney function (as measured by blood and urine tests), overall health, and personal preferences.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      KIDNEY TRANSPLANTATION",
"     </span>",
"    </p>",
"    <p>",
"     Kidney transplantation is considered the treatment of choice for many people with severe chronic kidney disease because quality of life and survival are often better than in people who use dialysis. However, there is a shortage of organs available for donation. Many people who are candidates for kidney transplantation are put on a transplant waiting list and require dialysis until an organ is available.",
"    </p>",
"    <p>",
"     A kidney can come from a living relative, a living unrelated person, or from a person who has died (deceased or cadaver donor); only one kidney is required to survive. In general, organs from living donors function better and for longer periods of time than those from donors who are deceased.",
"    </p>",
"    <p>",
"     Some people with renal failure are not candidates for a kidney transplant. Older age and severe heart or vascular disease may mean that it is safer to remain on dialysis rather than undergo kidney transplantation. Other conditions that might prevent a person from being eligible for kidney transplantation include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Active or recently treated cancer",
"      </li>",
"      <li>",
"       A chronic illness that could lead to death within a few years",
"      </li>",
"      <li>",
"       Poorly controlled mental illness (psychosis)",
"      </li>",
"      <li>",
"       Severe obesity (a body mass index greater than 40) (",
"       <a class=\"calc calc_patient\" href=\"UTD.htm?41/23/42366?source=see_link\">",
"        calculator 1",
"       </a>",
"       and",
"       <a class=\"calc calc_patient\" href=\"UTD.htm?36/47/37630?source=see_link\">",
"        calculator 2",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Inability to remember medications",
"      </li>",
"      <li>",
"       Current drug or alcohol abuse",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Some people with HIV infection may be eligible for kidney transplantation if their disease is well-controlled.",
"    </p>",
"    <p>",
"     People with other medical conditions are evaluated on a case-by-case basis to determine if kidney transplantation is an option.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Advantages",
"     </span>",
"     &nbsp;&mdash;&nbsp;Kidney transplantation is the treatment of choice for many people with end-stage renal disease. A successful kidney transplant can improve your quality of life and reduce your risk of dying from kidney disease. In addition, people who undergo kidney transplantation do not require hours of daily dialysis treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Disadvantages",
"     </span>",
"     &nbsp;&mdash;&nbsp;Kidney transplantation is a major surgical procedure that has risks both during and after the surgery. The risks of the surgery include infection, bleeding, and damage to the surrounding organs. Even death can occur, although this is very rare.",
"    </p>",
"    <p>",
"     After kidney transplantation, you will be required to take medications and have frequent monitoring to minimize the chance of organ rejection; this must continue for your entire lifetime. The medications can have significant and bothersome side effects.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      HEMODIALYSIS",
"     </span>",
"    </p>",
"    <p>",
"     In hemodialysis, your blood is pumped through a dialysis machine to remove waste products and excess fluids. You are connected to the dialysis machine using a surgically created path called a vascular access, usually referred to as an access. This allows blood to be removed from the body, circulate through the dialysis machine, and then return to the body.",
"    </p>",
"    <p>",
"     Hemodialysis can be done at a dialysis center or at home. When done in a center, it is generally done three times a week and takes between three and five hours per session. Home dialysis is generally done three to seven times per week and takes between three and ten hours per session (often while sleeping). More detailed information about hemodialysis is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=see_link\">",
"      \"Patient information: Hemodialysis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Advantages",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is not known if hemodialysis has clear advantages over the other type of dialysis (peritoneal dialysis) in terms of survival. The choice between the two types of dialysis is generally based upon other factors, including your preferences, home supports, and underlying medical problems. You should begin with the type of dialysis that you and your doctors think is best, although it is possible to switch to another type as circumstances and preferences change.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Disadvantages",
"     </span>",
"     &nbsp;&mdash;&nbsp;Low blood pressure is the most common complication of hemodialysis and can be accompanied by lightheadedness, shortness of breath, abdominal cramps, nausea, or vomiting. Treatments and preventive measures are available for these potential problems. In addition, the access can become infected or develop blood clots.",
"    </p>",
"    <p>",
"     Many patients who receive hemodialysis in a center are either unable to work or choose not to work due to the time required for travel and treatment.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      PERITONEAL DIALYSIS",
"     </span>",
"    </p>",
"    <p>",
"     Peritoneal dialysis (PD) is typically done at home. To perform PD, the abdominal cavity is filled with dialysis fluid (called dialysate) through a catheter (a flexible tube). The catheter is surgically inserted into the abdomen near the umbilicus (belly button). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=see_link\">",
"      \"Patient information: Peritoneal dialysis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The fluid is held within the abdomen for a prescribed period of time (called a dwell). The lining of the abdominal cavity (the peritoneal lining) acts as a membrane to allow excess fluids and waste products to diffuse from the bloodstream into the dialysate. The used dialysate in the abdomen is then drained out and discarded. The peritoneal cavity is then filled again with fresh dialysate. This process is called an exchange.",
"    </p>",
"    <p>",
"     The exchange may be done manually four to five times during the day. The exchange may also be done automatically using a machine (called a cycler) while you sleep.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Advantages",
"     </span>",
"     &nbsp;&mdash;&nbsp;Advantages of peritoneal dialysis compared to hemodialysis include more uninterrupted time for work, family, and social activities. Most people who use PD are able to continue working, at least part-time, especially if exchanges are done during sleep.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Disadvantages",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who use PD must be able to understand how to set the equipment up and use their hands to connect and disconnect small tubes. If you cannot do this, a family or household member may be able to do it.",
"    </p>",
"    <p>",
"     Disadvantages of peritoneal dialysis include an increased risk of hernia (weakening of the abdominal muscles) from the pressure of the fluid inside the abdominal cavity. In addition, you can gain weight and you have an increased risk of infection at the catheter site or inside the abdomen (peritonitis).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      WHICH THERAPY IS BEST FOR ME?",
"     </span>",
"    </p>",
"    <p>",
"     Kidney transplantation is the optimal treatment for most patients. Patients who are not candidates for kidney transplantation or who must wait for a kidney can usually be treated with either hemodialysis or peritoneal dialysis.",
"    </p>",
"    <p>",
"     Choosing between peritoneal dialysis and hemodialysis is a complex decision that is best made by you and your doctor, and often other family members or caregivers, after careful consideration of a number of important factors.",
"    </p>",
"    <p>",
"     For example, hemodialysis involves rapid changes of the fluid balance in the body and cannot be tolerated by some patients. Some patients are not suitable candidates for kidney transplantation, while others may not have the home supports or abilities needed to do peritoneal dialysis. Your overall medical condition, personal preferences, and home situation are among the many factors that should be considered. It is possible to switch from one type of dialysis to the other if preferences or conditions change over time.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      REFUSING DIALYSIS",
"     </span>",
"    </p>",
"    <p>",
"     In the United States, dialysis is available to everyone who needs it. However, some people choose to refuse dialysis. You and your family should discuss the risks and benefits of long-term dialysis early and often.",
"    </p>",
"    <p>",
"     Most people with kidney disease who have no other chronic illnesses are encouraged to pursue aggressive treatment of their disease; the chance of having a high quality of life for an extended period of time is usually excellent. However, you may have compelling reasons for refusing treatment. Try to feel comfortable discussing your wishes with your family and healthcare team with the goals of death with dignity and life with quality.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H141\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H203570077\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=see_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/44/35523?source=see_link\">",
"      Patient information: Polycystic kidney disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=see_link\">",
"      Patient information: Hemodialysis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/22/11619?source=see_link\">",
"      Patient information: Preparing for hemodialysis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/43/16051?source=see_link\">",
"      Patient information: Peritoneal dialysis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/42/19107?source=see_link\">",
"      Patient information: Choosing between dialysis and kidney transplant (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/15/12531?source=see_link\">",
"      Patient information: Planning for a kidney transplant (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H203570086\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=see_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=see_link\">",
"      Patient information: Peritoneal dialysis (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=see_link\">",
"      Adequacy of peritoneal dialysis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31286?source=see_link\">",
"      Choosing a modality for chronic peritoneal dialysis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34312?source=see_link\">",
"      Dialysis modality and patient outcome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30697?source=see_link\">",
"      Evaluation of the living kidney donor and risk of donor nephrectomy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=see_link\">",
"      Evaluation of the potential renal transplant recipient",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=see_link\">",
"      HLA and ABO sensitization and desensitization in renal transplantation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11159?source=see_link\">",
"      HLA matching and graft survival in kidney transplantation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4616?source=see_link\">",
"      Indications for initiation of dialysis in chronic kidney disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17992?source=see_link\">",
"      Patient survival after renal transplantation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/29/43480?source=see_link\">",
"      Renal transplantation and the elderly patient",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/61/15321?source=see_link\">",
"      Solid organ transplantation in HIV-infected individuals",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Kidney Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(800) 922-9010",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.kidney.org/\">",
"      www.kidney.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       United Network for Organ Sharing (UNOS)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(888) 894-6361",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.unos.org/\">",
"      www.unos.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Kidney Fund",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.akfinc.org/\">",
"      www.akfinc.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Home Dialysis Central",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.homedialysiscentral.org/\">",
"      www.homedialysiscentral.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Kidney School",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.kidneyschool.org/\">",
"      www.kidneyschool.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?9/26/9635/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 14, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?9/26/9635?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9635/abstract/1\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9635/abstract/2\">",
"      Galla JH. Clinical practice guideline on shared decision-making in the appropriate initiation of and withdrawal from dialysis. The Renal Physicians Association and the American Society of Nephrology. J Am Soc Nephrol 2000; 11:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9635/abstract/3\">",
"      Williams AW, Chebrolu SB, Ing TS, et al. Early clinical, quality-of-life, and biochemical changes of \"daily hemodialysis\" (6 dialyses per week). Am J Kidney Dis 2004; 43:90.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f9_26_9635=[""].join("\n");
var outline_f9_26_9635=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHEN WILL DIALYSIS OR KIDNEY TRANSPLANTATION BE NEEDED?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           KIDNEY TRANSPLANTATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           HEMODIALYSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           PERITONEAL DIALYSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           WHICH THERAPY IS BEST FOR ME?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           REFUSING DIALYSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        CALCULATORS",
"       </h1>",
"       <div id=\"relatedCalculators\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_patient\" href=\"UTD.htm?41/23/42366?source=related_link\" title=\"calculator 1\">",
"           Calculator: Body mass index for adults (Patient information)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_patient\" href=\"UTD.htm?36/47/37630?source=related_link\" title=\"calculator 2\">",
"           Calculator: Body mass index for adults (Metric, Patient information)",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f9_26_9636="Aluminum hydroxide and magnesium trisilicate: Patient drug information";
var content_f9_26_9636=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Aluminum hydroxide and magnesium trisilicate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/23/41333?source=see_link\">",
"     see \"Aluminum hydroxide and magnesium trisilicate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gaviscon&reg; Tablet [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10013950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691873",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heartburn and upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701479",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to aluminum, magnesium, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take other drugs within 1 hour of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        Products with aluminum and calcium:",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705591",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        Products with magnesium:",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694590",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chew or crush tablet well. Take with a full glass of water.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11053 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F9050627AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_26_9636=[""].join("\n");
var outline_f9_26_9636=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132621\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013950\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013952\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013951\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013956\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013957\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013959\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013954\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013955\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013960\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013961\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/23/41333?source=related_link\">",
"      Aluminum hydroxide and magnesium trisilicate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_26_9637="Mesothelioma MRI I";
var content_f9_26_9637=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66436%7EPULM%2F78690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66436%7EPULM%2F78690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mesothelioma on MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A coronal T1-weighted image shows a multilobular mass in the right paravertebral sulcus (arrow) extending into the minor fissure and along the diaphragm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mesothelioma with thickened fissures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal T2-weighted image shows high signal caused by tumor extending from the diaphragmatic pleura into the thickened major and minor fissures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_26_9637=[""].join("\n");
var outline_f9_26_9637=null;
var title_f9_26_9638="Promethazine, phenylephrine, and codeine: Patient drug information";
var content_f9_26_9638=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Promethazine, phenylephrine, and codeine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/29/22997?source=see_link\">",
"     see \"Promethazine, phenylephrine, and codeine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/53/43859?source=see_link\">",
"     see \"Promethazine, phenylephrine, and codeine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700251",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give to a child younger than 6 years of age. Very bad effects may happen. Follow how to use very closely and check all drugs with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop coughing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700969",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give this drug to a child younger than 6 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701853",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to codeine, phenylephrine, promethazine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703546",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A fast heartbeat, high blood pressure, or poor blood flow to the legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not for coughs due to smoking or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Parkinson's disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11846 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-6DAE62D42F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_26_9638=[""].join("\n");
var outline_f9_26_9638=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018058\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018060\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018059\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018064\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018065\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018067\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018062\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018063\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018068\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018069\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/29/22997?source=related_link\">",
"      Promethazine, phenylephrine, and codeine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/53/43859?source=related_link\">",
"      Promethazine, phenylephrine, and codeine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_26_9639="Liver in HELLP Light";
var content_f9_26_9639=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    HELLP syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Liver biopsy from a patient with HELLP syndrome. The zones immediately adjacent to the portal triads show collections of red blood cells, without inflammation or necrosis of hepatocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Caroline A Riely, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_26_9639=[""].join("\n");
var outline_f9_26_9639=null;
var title_f9_26_9640="CT scan pneumatosis coli";
var content_f9_26_9640=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F58309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F58309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    CT scan of pneumatosis coli",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 509px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography (CT) imaging of the abdomen is from a 55-year-old female who presented with acute abdominal pain and distension. Image A is a scout film of the abdomen and image B is a magnified view of the small bowel from the scout film. The images reveal air within the wall of the&nbsp;dilated loops of small-bowel, characteristic of pneumatosis intestinalis. The paucity of gas in the colon and rectum suggests SBO or severe ileus. Image C is coronal reformat through the abdomen confirming the accumulation of bubbles of air within the wall of the small bowel (white arrow). Image D is an axial image through the affected small bowel loop that shows more extensive accumulation of air within the wall of the thickened small bowel wall. Associated findings include decompressed large bowel (arrowheads), suggesting small bowel obstruction or severe ileus. In the appropriate clinical setting, the findings are highly suggestive of acute ischemia of the small bowel causing a severe ileus and functional obstruction. Less likely but also possible is small bowel obstruction with secondary ischemia.",
"    <div class=\"footnotes\">",
"     CT:&nbsp;computed tomography; SBO: small bowel obstruction.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_26_9640=[""].join("\n");
var outline_f9_26_9640=null;
var title_f9_26_9641="Clinical manifestations and diagnosis of polyarteritis nodosa";
var content_f9_26_9641=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of polyarteritis nodosa",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/26/9641/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/26/9641/contributors\">",
"     Peter A Merkel, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/26/9641/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/26/9641/contributors\">",
"     Gene G Hunder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/26/9641/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/26/9641/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/26/9641/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis that typically affects medium-sized muscular arteries, with occasional involvement of small muscular arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Unlike some other vasculitides (eg, microscopic polyarteritis, granulomatosis with polyangiitis [Wegener&rsquo;s]), polyarteritis nodosa is not associated with antineutrophil cytoplasmic antibodies (ANCA) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients typically present with systemic symptoms. The kidneys, skin, joints, muscles, nerves, and gastrointestinal tract are commonly involved, usually in some combination and sometimes all at once by the time of diagnosis. PAN can affect virtually any organ but has a striking tendency to spare the lungs. Clinical variants or subsets of PAN include single-organ disease and cutaneous-only PAN.",
"   </p>",
"   <p>",
"    The spectrum of disease known as PAN has evolved and narrowed substantially due to the identification and classification of other forms of vasculitis that had previously been considered PAN. Most importantly, the establishment and acceptance of microscopic polyangiitis as a distinct disease, and the routine availability and recognition of ANCA testing as critical to diagnosing vasculitides other than PAN, have led to more patients with vasculitis being classified as not having PAN. Patient cohorts of PAN included in case series and other research studies published prior to the 1990s almost certainly included a mixture of the newer definition of PAN with microscopic polyangiitis and possibly other forms of vasculitis. Thus, more recent case series of PAN that specifically exclude patients with MPA provide important updated information about this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of PAN will be reviewed here. Treatment is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28119?source=see_link\">",
"     \"Treatment and prognosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Microscopic polyangiitis and other ANCA-associated systemic vasculitides (eg, granulomatosis with polyangiitis [Wegener&rsquo;s] and Churg-Strauss syndrome) that characteristically affect small vessels such as arterioles, capillaries, and venules, as well as muscular arteries, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=see_link\">",
"     \"Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Population prevalence estimates for PAN range from 2 to 33 per million [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The annual incidence in three regions of Europe was estimated to be 4.4 to 9.7 per million [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/8\">",
"     8",
"    </a>",
"    ]. The variation in estimates may be partly explained by differences in diagnostic criteria, but regional variations also appear to exist [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. The marked reduction in hepatitis B virus infection in many parts of the world has been associated with a parallel reduction in prevalence of PAN.",
"   </p>",
"   <p>",
"    The diagnosis is most commonly made in middle aged or older adults, and the incidence rises with age, with a peak in the sixth decade of life [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/5,8,9\">",
"     5,8,9",
"    </a>",
"    ]. There appears to be a 1.5:1 male predominance. Children can also be affected by PAN. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40616?source=see_link\">",
"     \"Classification and incidence of childhood vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of PAN are idiopathic, although hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, and hairy cell leukemia are important in the pathogenesis of some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. PAN in these settings is called secondary PAN and is also discussed elsewhere in topics related to the underlying disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=see_link&amp;anchor=H5#H5\">",
"     \"Renal disease associated with hepatitis B virus infection\", section on 'Polyarteritis nodosa'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=see_link&amp;anchor=H5#H5\">",
"     \"Renal disease associated with hepatitis C virus infection\", section on 'Polyarteritis nodosa'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20841?source=see_link\">",
"     \"Clinical features and diagnosis of hairy cell leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one report from France, HBV accounted for one-third of the cases of PAN, but even higher prevalence rates are possible in areas with endemic HBV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/4,11\">",
"     4,11",
"    </a>",
"    ]. HBV-related PAN has the same clinical features as non-HBV-related PAN and typically occurs within four months after the onset of HBV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenetic mechanisms in PAN are poorly understood. It seems likely that in terms of pathogenesis and pathophysiology, PAN represents a spectrum of disease rather than a single entity. In some subsets of cases (eg, those associated with hepatitis B), immune complexes are thought to play a role. However, the mechanism(s) through which immune complex mediated disease leads to medium sized arterial inflammation and yet spares arterioles, capillaries, and venules in PAN is unknown. In other subsets of this disease, immune complexes may play a less central role.",
"   </p>",
"   <p>",
"    Thickening of the inflamed vessel wall and intimal proliferation can cause luminal narrowing, reducing blood flow and predisposing to thrombosis of affected vessels. The resulting ischemia or infarction of tissue causes varied clinical manifestations that are discussed in more detail below. As an example, involvement of branches of the renal arteries or intrarenal vessels such as the intralobular or arcuate arteries causes renal ischemia, activation of the renin-angiotensin system, and hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to arterial narrowing and thrombosis, inflammation can cause weakening of the vessel wall that leads to aneurysm formation. Aneurysmal rupture may result in life-threatening bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the initiating event or underlying cause, established PAN is characterized by segmental transmural inflammation of muscular arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/2\">",
"     2",
"    </a>",
"    ]. In contrast to some other forms of systemic vasculitis, PAN does not involve veins. The cellular infiltrate contains polymorphonuclear leukocytes and mononuclear cells. Fragments of white blood cells (leukocytoclasis) may be noted. Necrosis of the arterial wall results in a homogeneous, eosinophilic appearance referred to as fibrinoid necrosis. Disruption of the internal and external elastic lamina is noted and may contribute to the development of aneurysmal dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/16\">",
"     16",
"    </a>",
"    ]. Lesions that appear to be of different ages are typically found within a single sample. Granulomatous inflammation does not occur in PAN, and its presence suggests other diagnoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PAN typically present with systemic symptoms (fatigue, weight loss, weakness, fever, arthralgias) and signs (skin lesions, hypertension, renal insufficiency, neurologic dysfunction, abdominal pain) of multisystem involvement (",
"    <a class=\"graphic graphic_table graphicRef53997 \" href=\"UTD.htm?32/43/33468\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Skin disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin manifestations of PAN may include tender erythematous nodules, purpura, livedo reticularis, ulcers, and bullous or vesicular eruption [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/4,17,18\">",
"     4,17,18",
"    </a>",
"    ]. The nodules in PAN are reminiscent of erythema nodosum or nodular vasculitis, but adequate biopsy specimens demonstrate necrotizing vasculitis within the walls of medium-sized arteries, usually in the deep dermis or embedded between fat lobules in the subcutaneous fat. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17112?source=see_link&amp;anchor=H4122269#H4122269\">",
"     \"Panniculitis: Recognition and diagnosis\", section on 'Inflammatory disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The palpable purpuric lesions seen in PAN are identical to those seen in other forms of vasculitis usually associated with small vessel disease (eg, Henoch-Sch&ouml;nlein purpura, ANCA-associated vasculitis, and mixed cryoglobulinemia). Biopsy of these skin lesions reveals leukocytoclastic vasculitis, most prominent in the postcapillary venules (",
"    <a class=\"graphic graphic_picture graphicRef78697 \" href=\"UTD.htm?9/36/9794\">",
"     picture 1",
"    </a>",
"    ). Such findings illustrate that PAN does not exclusively involve medium-sized, muscular arteries and arterioles but also includes small arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/19\">",
"     19",
"    </a>",
"    ]. However, presentations consistent with only small-vessel involvement essentially exclude PAN.",
"   </p>",
"   <p>",
"    Skin lesions may be focal or diffuse and are more frequently and often more marked over the lower extremities. Limb edema is common. Progressive skin involvement may be severe, including infarction and gangrene of the fingers, toes, or other areas and ulceration extending into the subcutaneous tissue. However, digital and limb ischemia often reflects involvement of arteries larger than &ldquo;medium-sized&rdquo; skin vessels.",
"   </p>",
"   <p>",
"    Many of the skin manifestations of PAN result from involvement of vessels within the subcutaneous tissues. For nodules and ulcers, small 2 to 4 mm &ldquo;punch&rdquo; biopsies of the skin that sample only the epidermis and superficial dermis are unlikely to include muscular arteries and thus are of limited value. Elliptical surgical skin biopsies that include deeper dermis and subcutaneous fat may be more helpful in diagnosis. &ldquo;Medium-sized&rdquo; arteries in the skin may actually be quite small compared with other medium-sized arteries (such as coronary or mesenteric arteries), but they are still muscular and are larger than the small, superficial precapillary arteries associated with purpura.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In autopsy studies, the kidneys are the most commonly involved organ. Renal involvement frequently leads to variable degrees of renal insufficiency and hypertension. In addition, rupture of renal arterial aneurysms can cause perirenal hematomas. Multiple renal infarctions may also develop in those with severe vasculitis.",
"   </p>",
"   <p>",
"    Incomplete luminal narrowing of the inflamed arteries leads to glomerular ischemia but not inflammation or necrosis. Thus, the urinalysis, when abnormal, shows only sub-nephrotic and often minimal proteinuria and perhaps modest hematuria, but red blood cell casts (indicative of a glomerular focus of inflammation) are usually absent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In patients with red blood cell casts, alternative diagnoses should be considered, including ANCA-associated vasculitis or systemic lupus erythematosus.",
"   </p>",
"   <p>",
"    Hypertension is a common finding in patients with PAN and renal involvement. As noted above, renal ischemia, leading to activation of the renin-angiotensin system, is thought to be the primary mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neurologic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mononeuropathy multiplex (or asymmetric polyneuropathy) affecting named nerves (eg, radial, ulnar, peroneal), typically with both motor and sensory deficits, is one of the most common findings in patients with PAN, occurring in up to 70 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/4,20-22\">",
"     4,20-22",
"    </a>",
"    ]. The neuropathy is generally asymmetric at onset, but additional nerve branches become affected over time, leading to a more confluent distal symmetric polyneuropathy. Involvement of the central nervous system occurs in 5 to 10 percent of patients with PAN [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/4,23-25\">",
"     4,23-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Gastrointestinal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal pain is an early symptom in patients with mesenteric arteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/26\">",
"     26",
"    </a>",
"    ]. The discomfort may be intermittent or continuous and may be most prominent after meals (&ldquo;intestinal angina&rdquo;). Weight loss may ensue due to decreased food intake",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    malabsorption. Progressive disease can result in bowel infarction with perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other gastrointestinal symptoms that may be seen include nausea, vomiting, melena, bloody or nonbloody diarrhea, and life-threatening gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/28\">",
"     28",
"    </a>",
"    ]. Perforation during colonoscopy may be more frequent in patients with PAN. If colonoscopy is otherwise indicated in a patient with suspected or known PAN, minimal insufflation during the procedure and early termination of the study, if ischemic areas of bowel are noted, are recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ischemia due to vasculitis affects the small intestine more commonly than other areas of the gastrointestinal tract. In addition, a subset of patients has predominantly mesenteric arterial involvement with little or no clinical evidence of extraintestinal vasculitis. Rare presentations resembling acute cholecystitis or appendicitis result from acute vasculitis limited to the cystic or appendiceal artery, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Segmental pancreatic infarction and necrotizing pancreatitis, albeit rare, may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Coronary artery disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although overt myocardial infarction is uncommon, myocardial ischemia may result from narrowing or occlusion of the coronary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/30\">",
"     30",
"    </a>",
"    ]. Heart failure may result from either vasculitis of the coronary arteries, resulting in ischemic cardiomyopathy, or from uncontrolled hypertension caused by renal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Muscle disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle involvement is common; symptoms include myalgia and muscle weakness. Serum creatinine kinase levels may be elevated but are seldom high enough to trigger suspicion of an inflammatory myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/31\">",
"     31",
"    </a>",
"    ]. When muscle pain or claudication are present, muscle biopsy has an approximately 50 percent sensitivity for PAN [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually any organ of the body may be affected in patients with PAN:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Orchitis with testicular tenderness and pain occurs in more than 10 percent of patients, and testicular biopsy in patients with these symptoms can often be diagnostic of PAN [",
"      <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several abnormalities of the eye may occur, including ischemic retinopathy with hemorrhages and retinal detachment, as well as ischemic optic neuropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/34,35\">",
"       34,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Breast and uterine involvement may be seen in selected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Involvement of bronchial arteries has been described in PAN [",
"      <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/36\">",
"       36",
"      </a>",
"      ]. However, the presence of capillaritis or other lung parenchymal involvement by vasculitis strongly suggests another disease process, such as microscopic polyangiitis, granulomatosis with polyangiitis (Wegener&rsquo;s), or the Churg-Strauss syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Splenic infarction can occur due to arteritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical diagnosis of PAN is suspected based upon the presence of characteristic symptoms, physical findings, and compatible laboratory test results. However, because of the relative rarity of this disease and the potentially severe adverse effects related to treatment, the diagnosis should be confirmed by biopsy whenever possible. In the absence of an obvious site for tissue biopsy, angiography sometimes reveals microaneurysms of blood vessels in the renal, hepatic, or mesenteric circulations.",
"   </p>",
"   <p>",
"    A general approach to diagnosis in a patient suspected of having vasculitis is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link&amp;anchor=H21#H21\">",
"     \"Classification of and approach to the vasculitides in adults\", section on 'Diagnostic approach'",
"    </a>",
"    .) The following is a brief summary with a focus on those features considered to be of particular importance in PAN.",
"   </p>",
"   <p>",
"    Arteritis consistent with PAN can occur in individual organs without evident systemic involvement. Such cases may be discovered either through biopsy or angiography during an evaluation for vasculitis or &ldquo;incidentally&rdquo; upon pathologic review of a surgical specimen, sometimes obtained for other reasons. Whether to label such cases of medium-vessel vasculitis in a single organ as PAN is controversial. However, in all such cases, a comprehensive evaluation for other manifestations of PAN, as described in this section, is warranted to help establish the diagnosis and determine extent of disease to guide treatment plans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical history serves to identify clinical manifestations that might be due to PAN. It may also identify other possible causes of the patient&rsquo;s symptoms (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Differential diagnosis'",
"    </a>",
"    below) such as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drug exposure - Including prescription and illicit drugs associated with drug-induced vasculitis (eg, amphetamines), or injection drug use and the associated risk of hepatitis B and C virus infection. Almost every class of drugs has been implicated as possibly causal of vasculitis, but not all such drug-induced vasculitides fit the pattern of PAN.",
"     </li>",
"     <li>",
"      Alternative diagnosis &ndash; Other systemic inflammatory diseases (eg, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis), infectious diseases (eg, chronic viral hepatitis, bacterial endocarditis), embolic disorders (eg, atherosclerosis and recent arterial catheterization), or thrombotic disorders (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Differential diagnosis'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful physical examination helps to determine the extent of vascular lesions, the distribution of affected organs, and the presence of additional disease processes. Skin manifestations and the presence of objective evidence of motor weakness (eg, a foot- or wrist-drop) or sensory loss should be sought. A full vascular examination is warranted.",
"   </p>",
"   <p>",
"    If there is no evidence of overt gastrointestinal bleeding, a positive test for occult blood may be indicative of mesenteric vasculitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no diagnostic laboratory test for PAN. Basic laboratory tests help ascertain the extent of organs affected and their degree of involvement.",
"   </p>",
"   <p>",
"    Basic laboratory analysis includes serum creatinine, muscle enzyme concentrations, liver function studies, hepatitis (HBV and HCV) serologies, and urinalysis. Acute phase proteins are typically elevated, as evidenced by increased erythrocyte sedimentation rate and C reactive protein concentrations, but are neither sensitive nor specific enough for the diagnosis of PAN (or most other vasculitides) to substantially impact diagnostic decision making.",
"   </p>",
"   <p>",
"    Chest radiography is used to exclude diseases, particularly other forms of vasculitis with a greater propensity for involving the lungs. A baseline electrocardiogram is reasonable, even in the absence of cardiac symptoms.",
"   </p>",
"   <p>",
"    Blood cultures should be obtained in all patients suspected of having a systemic vasculitis in order to exclude endovascular infection.",
"   </p>",
"   <p>",
"    Additional laboratory testing is valuable in narrowing the differential diagnosis. This includes the following assays, depending upon the alternative diagnoses being considered based upon the patients signs and symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antineutrophil cytoplasmic antibodies (ANCA)",
"     </li>",
"     <li>",
"      Antinuclear antibodies (ANA)",
"     </li>",
"     <li>",
"      Complement components (C3 and C4)",
"     </li>",
"     <li>",
"      Cryoglobulins",
"     </li>",
"     <li>",
"      Serum and urine immunofixation electrophoresis to test for monoclonal gammopathy",
"     </li>",
"     <li>",
"      Testing for human immunodeficiency virus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A positive immunofluorescence test for ANCA, if confirmed by ELISA testing to be due to antibodies with specificity for proteinase-3 (PR3) or myeloperoxidase (MPO), strongly argues against PAN and in favor of one of the ANCA-associated vasculitides. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High titers of ANA suggest an underlying autoimmune disease such as systemic lupus erythematosus (SLE), systemic sclerosis (scleroderma), or an overlap syndrome, all of which may sometimes be associated with vasculitis. In patients with a positive ANA for whom there is clinical suspicion of a systemic rheumatic disease, additional serologic testing is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=see_link\">",
"     \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=see_link\">",
"     \"Measurement and clinical significance of antinuclear antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a patient with a history of inflammatory arthritis, testing for rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibodies is helpful when rheumatoid vasculitis is under consideration. RF is also positive in mixed cryoglobulinemia, which is usually associated with HCV. Mixed cryoglobulinemia is suggested by the presence of cryoglobulins and complement consumption. Although cryoglobulinemia is typically associated with small vessel disease (eg, glomerulonephritis, leukocytoclastic vasculitis, capillaritis), it has been linked to some cases of PAN, particularly in the setting of HCV or HBV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rheumatoid vasculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lyme disease is a consideration in patients with mononeuropathy multiplex or polyradiculopathy. Serologic testing for Lyme disease is probably unnecessary in the absence of neurologic involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link\">",
"     \"Clinical manifestations of Lyme disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HIV infection can cause mononeuritis multiplex, and co-infection with HIV is common among patients with HBV or HBC infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35864?source=see_link\">",
"     \"Epidemiology, pathogenesis and clinical features of HIV-associated neuropathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27848?source=see_link\">",
"     \"Diagnosis, treatment and prognosis of HIV-associated neuropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Tissue biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of PAN may be suspected from the clinical and radiologic findings, but the diagnosis should ideally be confirmed by biopsy of a clinically affected organ. Biopsy of clinically normal tissue has a much lower yield. This was illustrated in a retrospective study of patients with PAN, Churg-Strauss syndrome, and other systemic vasculitides with gastrointestinal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/26\">",
"     26",
"    </a>",
"    ]. Upper and lower gastrointestinal lesions, though frequently apparent at endoscopy, rarely provide histopathologic confirmation of vasculitis; none of the biopsies from the upper gastrointestinal tract obtained in 17 patients showed histologic signs of vasculitis. Colorectal biopsies, performed in six patients, were diagnostic in three (one with PAN and two with granulomatosis with polyangiitis [Wegener&rsquo;s]).",
"   </p>",
"   <p>",
"    Renal biopsy in classic polyarteritis nodosa may reveal pathognomonic inflammation of the medium-sized arteries (",
"    <a class=\"graphic graphic_picture graphicRef74893 \" href=\"UTD.htm?8/49/8985\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/37\">",
"     37",
"    </a>",
"    ]. Affected arteries may not be seen due to sampling error. However, the presence of small microaneurysms in the kidneys may increase the risk of bleeding from a renal biopsy; thus, some advocate performing a renal biopsy only in those patients in whom the arteriography is negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Arteriography and cross-sectional imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to biopsy for diagnosis is conventional mesenteric or renal arteriography [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These studies will often be diagnostic, demonstrating multiple aneurysms and irregular constrictions in the larger vessels with occlusion of smaller penetrating arteries (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65987 \" href=\"UTD.htm?35/54/36705\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Less invasive angiography techniques (eg, computed tomography [CT] and MRI), can also be used [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In the proper clinical setting, the finding of wedge-shaped areas of ischemia in the kidney may be of value in demonstrating renal vascular involvement. The demonstration of renal infarctions, however, is less specific for PAN than are the microaneurysms demonstrated most readily by conventional arteriography. CT and MR angiography continue to improve with respect to resolution for vascular disease and utility to both establish the extent of disease in PAN and to allow for serial images to track disease course and treatment response. These techniques have the advantage of helping to avoid repeat catheter-based angiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of PAN is broad, including infectious diseases that affect the vasculature or are complicated by systemic vasculitis. Immunosuppressive therapies that might be appropriate for systemic vasculitis may mask the symptoms and delay the diagnosis of an infectious disease. Noninfectious disorders, particularly those that can cause widespread arterial embolism, thrombosis, or vasospasm, must be considered as these diseases are also not appropriately treated with immunosuppression. Other systemic vasculitides, although treated in a similar fashion to PAN, may have distinctive manifestations. The differential diagnosis of vasculitis is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link&amp;anchor=H42#H42\">",
"     \"Classification of and approach to the vasculitides in adults\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among infectious diseases, the following may cause clinical manifestations that either mimic vasculitis or cause vascular inflammation:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infective endocarditis or other bacteremic disease",
"     </li>",
"     <li>",
"      Mycotic aneurysm with distal embolization",
"     </li>",
"     <li>",
"      Hepatitis B or C virus infection",
"     </li>",
"     <li>",
"      HIV infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other disorders that may mimic vasculitis of medium sized arteries include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atherosclerosis",
"     </li>",
"     <li>",
"      Embolic diseases (eg, left atrial myxoma, cholesterol crystals)",
"     </li>",
"     <li>",
"      Thrombotic disorders (eg, catastrophic antiphospholipid syndrome)",
"     </li>",
"     <li>",
"      Fibromuscular dysplasia",
"     </li>",
"     <li>",
"      Ergotism",
"     </li>",
"     <li>",
"      Radiation fibrosis",
"     </li>",
"     <li>",
"      Necrotic arachnidism (Loxosceles species spider bites)",
"     </li>",
"     <li>",
"      Malignant atrophic papulosis (Degos disease or syndrome)",
"     </li>",
"     <li>",
"      Other causes of malignant hypertension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other systemic vasculitides to consider are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </li>",
"     <li>",
"      Churg Strauss syndrome",
"     </li>",
"     <li>",
"      Henoch-Sch&ouml;nlein purpura",
"     </li>",
"     <li>",
"      Cryoglobulinemic vasculitis",
"     </li>",
"     <li>",
"      Drug-induced vasculitis",
"     </li>",
"     <li>",
"      Vasculitis secondary to connective tissue disease (eg, SLE, RA)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Glomerulonephritis is much more typical of microscopic polyangiitis than PAN. Among patients with glomerulonephritis, the urinalysis typically has mild to moderate proteinuria, with an active sediment containing red cells and cellular and granular casts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H2#H2\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Clinical patterns of glomerular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A mononeuropathy multiplex (or asymmetric polyneuropathy) with motor and sensory deficits is one of the most common findings in patients with PAN [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. If present, this finding is highly suggestive of vasculitis; diabetic neuropathy is the only other common cause of this problem in developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/40\">",
"     40",
"    </a>",
"    ]. Other forms of systemic vasculitis commonly associated with mononeuropathy multiplex are the ANCA-associated vasculitides and mixed cryoglobulinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Classification criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Rheumatology (ACR) has established ten criteria for the classification of polyarteritis nodosa in a patient with a vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/41\">",
"     41",
"    </a>",
"    ]. A sensitivity and specificity for the diagnosis of polyarteritis of 82 and 87 percent, respectively, has been found in the patient",
"    <strong>",
"     with a documented vasculitis",
"    </strong>",
"    in whom",
"    <strong>",
"     at least three",
"    </strong>",
"    of the following criteria are present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Otherwise unexplained weight loss greater than 4 kg",
"     </li>",
"     <li>",
"      Livedo reticularis",
"     </li>",
"     <li>",
"      Testicular pain or tenderness",
"     </li>",
"     <li>",
"      Myalgias (excluding that of the shoulder and hip girdle), weakness of muscles, tenderness of leg muscles, or polyneuropathy",
"     </li>",
"     <li>",
"      Mononeuropathy or polyneuropathy",
"     </li>",
"     <li>",
"      New onset diastolic blood pressure greater than 90 mmHg",
"     </li>",
"     <li>",
"      Elevated levels of serum blood urea nitrogen (&gt;40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or 14.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or creatinine (&gt;1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or 132",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Evidence of hepatitis B virus infection via serum antibody or antigen serology",
"     </li>",
"     <li>",
"      Characteristic arteriographic abnormalities not resulting from noninflammatory disease processes (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65987 \" href=\"UTD.htm?35/54/36705\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A biopsy of small or medium-sized artery containing polymorphonuclear cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PAN was defined by the Chapel Hill Consensus Conference (CHCC) as: &ldquo;Necrotizing inflammation of medium-sized or small arteries without glomerulonephritis or vasculitis in arterioles, capillaries, or venules&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to remember that neither the ACR Classification Criteria nor the CHCC nomenclature was meant to be used for the diagnosis of vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9641/abstract/43\">",
"     43",
"    </a>",
"    ]. Until validated diagnostic criteria for PAN are established, the diagnosis of PAN is informed by the ACR and CHCC approaches but remains a clinical diagnosis that importantly includes exclusion of entities that mimic this rare disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/59/9138?source=see_link\">",
"       \"Patient information: Polyarteritis nodosa (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=see_link\">",
"       \"Patient information: Vasculitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95198853\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis that typically affects medium-sized muscular arteries, with occasional involvement of small muscular arteries. The spectrum of disease known as PAN has evolved and narrowed substantially due to the identification and classification of other forms of vasculitis that had previously been considered PAN, particularly microscopic polyangiitis (MPA). Unlike MPA, PAN is not associated with the presence of antineutrophil cytoplasmic antibodies (ANCA). The diagnosis is most commonly made in middle-aged or older adults, and the incidence rises with age, with a peak in the sixth decade of life. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of PAN are idiopathic, although hepatitis B virus infection, hepatitis C virus infection, and hairy cell leukemia are important in the pathogenesis of some cases, which are termed secondary PAN. The pathogenetic mechanisms in PAN are poorly understood. It seems likely that, in terms of pathogenesis and pathophysiology, PAN represents a spectrum of disease rather than a single entity. Regardless of the underlying cause, established PAN is characterized by segmental transmural inflammation of muscular arteries; it does not involve veins, unlike other forms of systemic vasculitis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with PAN typically present with systemic symptoms (fatigue, weight loss, weakness, fever, arthralgias) and signs (skin lesions, hypertension, renal insufficiency, neurologic dysfunction, abdominal pain) of multisystem involvement (",
"      <a class=\"graphic graphic_table graphicRef53997 \" href=\"UTD.htm?32/43/33468\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A clinical diagnosis of PAN is suspected based upon the presence of characteristic symptoms, physical findings, and compatible laboratory test results. However, because of the relative rarity of this disease and because of the potentially severe adverse effects related to treatment, the diagnosis should be confirmed by biopsy whenever possible. In the absence of an obvious site for tissue biopsy, angiography sometimes reveals microaneurysms of blood vessels in the renal, hepatic, or mesenteric circulations. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of PAN is informed by the classification criteria developed by the American College of Rheumatology and by the definitions and nomenclature of the Chapel Hill Consensus Conference, but there are no validated diagnostic criteria for PAN. Thus, the diagnosis remains a clinical diagnosis that importantly includes exclusion of entities that mimic this rare disease. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Classification criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of PAN is broad, including infectious diseases that affect the vasculature or that are complicated by systemic vasculitis; noninfectious disorders, particularly those that can cause widespread arterial embolism, thrombosis, or vasospasm; and other systemic vasculitides. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/1\">",
"      Balow JE. Renal vasculitis. Kidney Int 1985; 27:954.",
"     </a>",
"    </li>",
"    <li>",
"     Sato O, Cohn DL. Polyarteritis and microscopic polyangiitis. In: Rheumatology, Klippel JH, Dieppe PA (Eds), Mosby, St Louis 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/3\">",
"      Kallenberg CG, Brouwer E, Weening JJ, Tervaert JW. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 1994; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/4\">",
"      Pagnoux C, Seror R, Henegar C, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 2010; 62:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/5\">",
"      Mahr A, Guillevin L, Poissonnet M, Aym&eacute; S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004; 51:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/6\">",
"      Reinhold-Keller E, Zeidler A, Gutfleisch J, et al. Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology (Oxford) 2000; 39:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/7\">",
"      Haugeberg G, Bie R, Bendvold A, et al. Primary vasculitis in a Norwegian community hospital: a retrospective study. Clin Rheumatol 1998; 17:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/8\">",
"      Watts RA, Lane SE, Scott DG, et al. Epidemiology of vasculitis in Europe. Ann Rheum Dis 2001; 60:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/9\">",
"      Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 2000; 43:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/10\">",
"      Watts RA, Gonzalez-Gay MA, Lane SE, et al. Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann Rheum Dis 2001; 60:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/11\">",
"      Guillevin L, Mahr A, Callard P, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/12\">",
"      Ramos-Casals M, Mu&ntilde;oz S, Medina F, et al. Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol 2009; 36:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/13\">",
"      Hasler P, Kistler H, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum 1995; 25:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/14\">",
"      Carpenter MT, West SG. Polyarteritis nodosa in hairy cell leukemia: treatment with interferon-alpha. J Rheumatol 1994; 21:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/15\">",
"      Stockigt JR, Topliss DJ, Hewett MJ. High-renin hypertension in necrotizing vasculitis. N Engl J Med 1979; 300:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/16\">",
"      Ng WF, Chow LT, Lam PW. Localized polyarteritis nodosa of breast--report of two cases and a review of the literature. Histopathology 1993; 23:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/17\">",
"      Gibson LE, Su WP. Cutaneous vasculitis. Rheum Dis Clin North Am 1995; 21:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/18\">",
"      Karlsberg PL, Lee WM, Casey DL, et al. Cutaneous vasculitis and rheumatoid factor positivity as presenting signs of hepatitis C virus-induced mixed cryoglobulinemia. Arch Dermatol 1995; 131:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/19\">",
"      Leavitt RY, Fauci AS. Polyangiitis overlap syndrome. Classification and prospective clinical experience. Am J Med 1986; 81:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/20\">",
"      Ohkoshi N, Mizusawa H, Oguni E, Shoji S. Sural nerve biopsy in vasculitic neuropathies: morphometric analysis of the caliber of involved vessels. J Med 1996; 27:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/21\">",
"      Tervaert JW, Kallenberg C. Neurologic manifestations of systemic vasculitides. Rheum Dis Clin North Am 1993; 19:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/22\">",
"      Moore PM. Neurological manifestation of vasculitis: update on immunopathogenic mechanisms and clinical features. Ann Neurol 1995; 37 Suppl 1:S131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/23\">",
"      Provenzale JM, Allen NB. Neuroradiologic findings in polyarteritis nodosa. AJNR Am J Neuroradiol 1996; 17:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/24\">",
"      Cohen RD, Conn DL, Ilstrup DM. Clinical features, prognosis, and response to treatment in polyarteritis. Mayo Clin Proc 1980; 55:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/25\">",
"      Reichart MD, Bogousslavsky J, Janzer RC. Early lacunar strokes complicating polyarteritis nodosa: thrombotic microangiopathy. Neurology 2000; 54:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/26\">",
"      Pagnoux C, Mahr A, Cohen P, Guillevin L. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore) 2005; 84:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/27\">",
"      Zizic TM, Classen JN, Stevens MB. Acute abdominal complications of systemic lupus erythematosus and polyarteritis nodosa. Am J Med 1982; 73:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/28\">",
"      Levine SM, Hellmann DB, Stone JH. Gastrointestinal involvement in polyarteritis nodosa (1986-2000): presentation and outcomes in 24 patients. Am J Med 2002; 112:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/29\">",
"      Flaherty J, Bradley EL 3rd. Acute pancreatitis as a complication of polyarteritis nodosa. Int J Pancreatol 1999; 25:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/30\">",
"      Kastner D, Gaffney M, Tak T. Polyarteritis nodosa and myocardial infarction. Can J Cardiol 2000; 16:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/31\">",
"      Plumley SG, Rubio R, Alasfar S, Jasin HE. Polyarteritis nodosa presenting as polymyositis. Semin Arthritis Rheum 2002; 31:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/32\">",
"      Fort JG, Griffin R, Tahmoush A, Abruzzo JL. Muscle involvement in polyarteritis nodosa: report of a patient presenting clinically as polymyositis and review of the literature. J Rheumatol 1994; 21:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/33\">",
"      Teichman JM, Mattrey RF, Demby AM, Schmidt JD. Polyarteritis nodosa presenting as acute orchitis: a case report and review of the literature. J Urol 1993; 149:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/34\">",
"      Akova YA, Jabbur NS, Foster CS. Ocular presentation of polyarteritis nodosa. Clinical course and management with steroid and cytotoxic therapy. Ophthalmology 1993; 100:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/35\">",
"      Hsu CT, Kerrison JB, Miller NR, Goldberg MF. Choroidal infarction, anterior ischemic optic neuropathy, and central retinal artery occlusion from polyarteritis nodosa. Retina 2001; 21:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/36\">",
"      Boki KA, Dafni U, Karpouzas GA, et al. Necrotizing vasculitis in Greece: clinical, immunological and immunogenetic aspects. A study of 66 patients. Br J Rheumatol 1997; 36:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/37\">",
"      Jennette JC, Falk RJ. The pathology of vasculitis involving the kidney. Am J Kidney Dis 1994; 24:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/38\">",
"      Kato T, Fujii K, Ishii E, et al. A case of polyarteritis nodosa with lesions of the superior mesenteric artery illustrating the diagnostic usefulness of three-dimensional computed tomographic angiography. Clin Rheumatol 2005; 24:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/39\">",
"      Schmidt WA. Use of imaging studies in the diagnosis of vasculitis. Curr Rheumatol Rep 2004; 6:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/40\">",
"      Hellmann DB, Laing TJ, Petri M, et al. Mononeuritis multiplex: the yield of evaluations for occult rheumatic diseases. Medicine (Baltimore) 1988; 67:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/41\">",
"      Lightfoot RW Jr, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990; 33:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/42\">",
"      Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9641/abstract/43\">",
"      Watts RA, Suppiah R, Merkel PA, Luqmani R. Systemic vasculitis--is it time to reclassify? Rheumatology (Oxford) 2011; 50:643.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8245 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-DA0D917308-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_26_9641=[""].join("\n");
var outline_f9_26_9641=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H95198853\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Skin disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neurologic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Muscle disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Tissue biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Arteriography and cross-sectional imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Classification criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95198853\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/8245\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8245|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/54/36705\" title=\"diagnostic image 1\">",
"      Renal arteriogram in polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8245|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/36/9794\" title=\"picture 1\">",
"      Leukocytoclastic vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/49/8985\" title=\"picture 2\">",
"      Polyarteritis nodosa (light micrograph)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8245|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/43/33468\" title=\"table 1\">",
"      Manifestations of PAN",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=related_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40616?source=related_link\">",
"      Classification and incidence of childhood vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20841?source=related_link\">",
"      Clinical features and diagnosis of hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=related_link\">",
"      Clinical manifestations and diagnosis of rheumatoid vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=related_link\">",
"      Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=related_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=related_link\">",
"      Diagnosis of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27848?source=related_link\">",
"      Diagnosis, treatment and prognosis of HIV-associated neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35864?source=related_link\">",
"      Epidemiology, pathogenesis and clinical features of HIV-associated neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17112?source=related_link\">",
"      Panniculitis: Recognition and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=related_link\">",
"      Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/59/9138?source=related_link\">",
"      Patient information: Polyarteritis nodosa (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=related_link\">",
"      Patient information: Vasculitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=related_link\">",
"      Renal disease associated with hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=related_link\">",
"      Renal disease associated with hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28119?source=related_link\">",
"      Treatment and prognosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_26_9642="Acute hemodialysis prescription";
var content_f9_26_9642=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute hemodialysis prescription",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/26/9642/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/26/9642/contributors\">",
"     Phillip Ramos, MD, MSCI",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/26/9642/contributors\">",
"     Mark R Marshall, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/26/9642/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/26/9642/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/26/9642/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/26/9642/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/26/9642/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/26/9642/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/26/9642/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/26/9642/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute renal failure (ARF) is a major cause of morbidity and mortality, particularly in the hospital setting. Despite improvements in renal replacement therapy (RRT) techniques during the last several decades, the mortality rate associated with ARF in critically ill patients remains above 50 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4553?source=see_link\">",
"     \"Renal and patient outcomes after acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RRT is ideally initiated in the acute setting prior to the dangerous accumulation of extravascular volume",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    uremic toxins that can result in further multi-organ damage and failure. Once the decision to initiate RRT has been made, the specific modality of dialytic support must be chosen. This consists of peritoneal dialysis, intermittent hemodialysis and its variations (eg, hemofiltration), and continuous renal replacement therapy. Once the selection is made, the acute dialysis prescription can be determined.",
"   </p>",
"   <p>",
"    An acute hemodialysis treatment is defined as a hemodialysis session specifically performed for ARF (also known as acute kidney injury [AKI]) or in the setting of a hospitalized end stage renal disease (ESRD) patient. The choice of specific dialysis modality, particularly the choice between continuous or intermittent dialysis, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28295?source=see_link\">",
"     \"Continuous renal replacement therapy in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The various components of the acute hemodialysis prescription will be described here. The use of peritoneal dialysis in ARF is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12169?source=see_link\">",
"     \"Use of peritoneal dialysis for the treatment of acute kidney injury (acute renal failure)\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urgent indications for RRT in patients with ARF generally include volume overload refractory to diuretics, hyperkalemia, metabolic acidosis, uremia, and toxic overdose of a dialyzable drug. In an attempt to minimize morbidity, dialysis should be started prior to the onset of overt complications of renal failure, whenever possible. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link&amp;anchor=H2#H2\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\", section on 'Indications for and timing of initiation of dialysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MODALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the decision to initiate RRT has been made, the specific modality of dialytic support must be chosen. The possibilities include peritoneal dialysis, intermittent hemodialysis and its variations (eg, hemofiltration), and continuous renal replacement therapy. Once this selection is made, the acute dialysis prescription can be determined. The determining factors of which modality is chosen include the catabolic state, hemodynamic stability, and whether the primary goal is solute removal (eg, uremia, hyperkalemia), fluid removal, or both. This is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     VASCULAR ACCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When acute hemodialysis is chosen as the dialytic support modality, vascular access must be established prior to initiating treatment. Placement of the venous dialysis catheter must be considered carefully, especially in the critically ill patient.",
"   </p>",
"   <p>",
"    The location depends upon factors such as body habitus, whether the patient is ambulatory or bed-ridden, presence of vascular disease or atypical anatomy, and the avoidance of specific complications in an at-risk patient (eg, risk of pneumothorax while placing a subclavian venous dialysis catheter in a patient with severe chronic obstructive pulmonary disease or history of deep vein thrombosis or other venous disease).",
"   </p>",
"   <p>",
"    For hospitalized ESRD patients, daily reassessment of the existing angioaccess (eg, arteriovenous graft or fistula) is appropriate. Many events during the hospitalization can jeopardize the existing access (eg, hypotension). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=see_link\">",
"     \"Overview of central catheters for acute and chronic hemodialysis access\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HEMODIALYZER MEMBRANES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of ARF, the choice of artificial membranes utilized may have a bearing on clinical outcome. Previously, it was postulated that non-complement activating membranes may incur less inflammatory risk with resultant decrease in infectious complications and possibly an increased probability of improved restoration of renal function. However, there are inconsistent findings concerning the effect of membrane biocompatibility on outcomes among patients with acute renal failure, with several meta-analyses reporting disparate results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=see_link&amp;anchor=H7#H7\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\", section on 'Complement activation, membrane biocompatibility, renal recovery, and survival'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Membranes can also be of low or high flux. High flux membranes contain large pores that allow for enhanced permeability of larger molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/1\">",
"     1",
"    </a>",
"    ]. Although this property can enhance removal of putative toxins and improve outcome, it could also allow the back transport (from dialysate to blood) of potentially harmful water-borne molecules. This property is a factor that confounds some of the conclusions from previously performed studies. Certainly, having the purest dialysate water possible should be a goal when using these more porous membranes to utilize their positive attributes and to minimize their potential risks.",
"   </p>",
"   <p>",
"    Overall, there are theoretical advantages to high flux biocompatible membranes that have not been consistently corroborated by often underpowered or flawed clinical studies. However, the effect of membrane biocompatibility on outcomes (when present) is consistently beneficial. In addition, since such membranes can now be obtained cheaply, cost has been eliminated as a deciding factor.",
"   </p>",
"   <p>",
"    We therefore suggest the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the water system used is high quality, high flux biocompatible dialysis membranes should be used in the ARF setting.",
"     </li>",
"     <li>",
"      If the water system is not of high quality, low flux biocompatible dialysis membranes should be used. Another option is the use of in-line membrane filtration devices on dialysis machines to generate ultrapure dialysate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=see_link&amp;anchor=H7#H7\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\", section on 'Complement activation, membrane biocompatibility, renal recovery, and survival'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=see_link&amp;anchor=H8#H8\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\", section on 'Membranes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10775?source=see_link\">",
"     \"Maintaining water quality for hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIALYSATE COMPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dialysate solution composition consists of potassium, sodium, bicarbonate buffer, calcium, magnesium, chloride, and glucose. Unlike chronic hemodialysis, the dialysate composition in acute hemodialysis is routinely altered each treatment to correct the metabolic abnormalities that can rapidly develop during ARF. This is particularly true in the treatment of potassium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     acid/base",
"    </span>",
"    derangements. Thus, the dialysate potassium, sodium, bicarbonate, and calcium are routinely changed in this setting.",
"   </p>",
"   <p>",
"    Issues surrounding magnesium, chloride, and glucose include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The usual dialysate magnesium concentration is 0.5 to 1.0",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      and is not usually different from that in the chronic setting.",
"     </li>",
"     <li>",
"      The amount of dialysate chloride is dependent upon the dialysate sodium and bicarbonate concentrations.",
"     </li>",
"     <li>",
"      The standard dialysate glucose concentration is 200",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      but may be decreased to more efficiently lower the serum potassium during hemodialysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dialysate potassium concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no standard dialysate potassium concentration in the acute hemodialysis prescription because of wide variability in serum potassium prior to initiating the hemodialysis session. It is crucial to know the predialysis serum potassium level at the start of the hemodialysis session to tailor the dialysate potassium so that normokalemia will be attained with avoidance of hypokalemia.",
"   </p>",
"   <p>",
"    The goal of an acute hemodialysis treatment is not necessarily to lower the total body potassium burden for general nutritional purposes. Instead, the goals are often more short term, such as normalizing the serum potassium level for the next 24 hours.",
"   </p>",
"   <p>",
"    The typical potassium concentration in the dialysate for acute hemodialysis ranges from 2.0 to 4.0",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    However, the dialysate potassium concentration should be varied based upon the pre-dialysis value [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/2\">",
"     2",
"    </a>",
"    ]. As described below, the dialysate glucose concentration can be another determinant of the rate of potassium removal.",
"   </p>",
"   <p>",
"    The prescribed dialysate bath potassium is determined by both the absolute serum potassium and the rate of rise in the inter-dialytic period. A rapid rate of rise in serum potassium may best be treated by daily hemodialysis rather than lowering the dialysate potassium bath concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Acute or severe hyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with acute",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe hyperkalemia have muscle weakness and cardiac conduction abnormalities, and should be treated with more rapidly acting medical therapies prior to the initiation of dialysis. The first electrocardiographic changes with hyperkalemia are tall peaked T waves (",
"    <a class=\"graphic graphic_waveform graphicRef80441 \" href=\"UTD.htm?11/50/12068\">",
"     waveform 1",
"    </a>",
"    ) and shortened QT interval. This is followed by progressive lengthening of the PR interval and QRS duration, and then loss of the P wave with further prolongation of the QRS interval (\"sine wave\" pattern). Conduction delay can manifest as bundle branch or AV nodal block, and ventricular fibrillation or asystole can result. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44069?source=see_link\">",
"     \"Clinical manifestations of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If more advanced electrocardiographic features of hyperkalemia are present, medical management should be initiated immediately with continuous ECG monitoring. Medical therapy is administered while emergency hemodialysis is being arranged. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there is no general consensus concerning the optimal strategy, the following is our general approach to the dialysate potassium concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Predialysis potassium &lt;4.0",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      &mdash; If the predialysis serum potassium level is less than 4.0",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      we recommend that the dialysate potassium bath should be adjusted to 4.0",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/2\">",
"       2",
"      </a>",
"      ]. This is done to prevent the development of hypokalemia and its complications.",
"     </li>",
"     <li>",
"      Predialysis potassium between 4.0 and 5.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      &mdash; If the predialysis serum potassium level is between 4.0 and 5.5",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      the typical potassium concentration in the dialysate for acute hemodialysis usually ranges from 2.0 to 4.0",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      We suggest using a dialysate potassium of 3.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      if the predialysis serum potassium is between 4.0 to 4.5",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      and 3.0",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      if the predialysis serum potassium is between 4.5 to 5.5",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      However, if a rapid increase in extracellular potassium is anticipated prior to the next hemodialysis session (eg, due to marked rhabdomyolysis), then a dialysate potassium of 2.0",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      should be used to ensure normokalemia in the lower range of normal.",
"     </li>",
"     <li>",
"      Predialysis potassium &gt;5.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      and &lt;8.0",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      &mdash; If patients have a predialysis serum potassium level greater than 5.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      and less than 8.0",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      then a 2.0",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      dialysate potassium bath should be used. However, the dialysate concentration should be increased to 2.5 or 3.0",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in patients at risk for cardiac arrhythmia or those receiving digitalis&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Complications with potassium removal'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Severe hyperkalemia, potassium &gt;8.0",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      &mdash; In cases of severe hyperkalemia (eg, &gt;8.0",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      a dialysate potassium concentration of 1.0",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      can be used to rapidly decrease the serum potassium to a more tolerable level. However, this should be done with a high degree of caution to avoid hypokalemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although rarely recommended, a zero potassium bath has also been used to rapidly decrease the serum potassium in a short period of time [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. After four hours of hemodialysis in one study, for example, a dialysate free of potassium was more effective than a 1.0 or 2.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    potassium dialysate bath in removing serum potassium, removing 85 percent more potassium than a 2.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    bath and 46 percent more than a 1.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    bath [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, to minimize the risk of hypokalemia and dialysis-induced arrhythmias, we do NOT recommend use of a zero potassium dialysate bath for the treatment of severe hyperkalemia. If a rapid fall in serum potassium is desired because of severe hyperkalemia, we suggest using a 1.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    potassium bath and checking a serum potassium every 30 to 60 minutes. Once the serum potassium is between 6 and 7",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    the dialysate potassium concentration can be changed to 2.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    for the remainder of the hemodialysis session, depending upon many other prescriptive components discussed below.",
"   </p>",
"   <p>",
"    In patients with underlying cardiac disorders or those taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , the dialysate concentration can be changed to 3.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    once the serum potassium is approximately 5.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    to avoid possibly life-threatening arrhythmias, with the postdialysis serum potassium goal of 4.0",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    Although not studied in the acute setting, this overall approach decreases the risk of hypokalemia and dialysis-induced arrhythmias, particularly in patients with predisposing risk factors delineated below. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Complications with potassium removal'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The amount of potassium removal is proportional to the gradient between the serum and dialysate concentrations. The administration of insulin, intravenous glucose, beta-agonists, or bicarbonate either concurrently or prior to hemodialysis results in intracellular translocation of potassium, lower serum levels, and therefore lower rates of potassium removal during dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Dialysate glucose concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dialysate glucose concentration is another factor that can modulate potassium removal, since the glucose load enhances insulin secretion which drives potassium into the cells. Thus, in the presence of endogenous insulin, the standard dialysate glucose concentration (200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [11.1",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    results in significantly decreased potassium removal relative to glucose-free dialysate solution [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, in cases of severe hyperkalemia where potassium removal is critical, a lower dialysate glucose concentration may be used. We suggest a dialysate glucose concentration of 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    if severe hyperkalemia (eg, &gt;8.0",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    is present. We do NOT use glucose-free dialysate because of the risk of hypoglycemia. Standard dialysate glucose concentration (200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [11.1",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    should be used in cases of mild to moderate hyperkalemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Complications with potassium removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hemodialysis treatment can provoke ventricular arrhythmias, which are related to dialysis-induced reductions in the serum potassium. Multiple studies have demonstrated that potentially life-threatening dialysis-induced arrhythmias with potassium removal are independently associated with risk factors such as coronary artery disease, left ventricular hypertrophy (LVH),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    use, hypertension, and advanced age [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study in chronic dialysis, for example, 23 stable ESRD patients were evaluated using a Holter monitor [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/7\">",
"     7",
"    </a>",
"    ]. Nine (39 percent) had ventricular tachycardia (VT) during and after hemodialysis performed with a dialysate potassium concentration of 2.0",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    Episodes of frequent or complex ventricular arrhythmias were more likely in patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    <span class=\"nowrap\">",
"     (8/9",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     1/14",
"    </span>",
"    without arrhythmias) and those with LVH",
"    <span class=\"nowrap\">",
"     (9/9",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     7/14",
"    </span>",
"    without arrhythmias). It was concluded that a low dialysate potassium concentration can induce ventricular arrhythmias in hemodialysis patients on digoxin and with LVH. It is unknown if, in the absence of underlying risk factors (cardiac arrhythmias, digoxin, or heart disease), a dialysate potassium concentration of 2.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    causes serious ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To lower the risk of potentially life-threatening dialysis-induced arrhythmias among patients with underlying risk factors, the goal is to obtain a postdialysis serum potassium concentration of approximately 4.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    by using a dialysate potassium concentration no lower than 3.0",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"   </p>",
"   <p>",
"    Periodic measurements of postdialysis potassium may be helpful. The immediate postdialysis value is generally the lowest and potassium rebound, while rapid, depends upon the factors previously discussed. However, the degree of potassium rebound is highly variable. Poor perfusion states and underlying illnesses all affect potassium rebound.",
"   </p>",
"   <p>",
"    Poor systemic perfusion may have a potentially large impact in two ways. First, potassium removal during hemodialysis is associated with a larger reduction in serum potassium due to less potassium efflux from cells. Second, after dialysis, potassium rebound will be less by the same mechanism. Such patients warrant closer monitoring of the serum potassium, with a postdialysis measurement at two to four hours. Additional issues related to postdialysis rebound are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment and prevention of hyperkalemia in adults\", section on 'Postdialysis potassium rebound'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, we recommend that patients with underlying cardiac disorders who undergo acute hemodialysis should be placed on a cardiac rhythm monitor during the dialysis session.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sodium modeling and hemodialysis hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of the dialysate sodium concentration can have a significant impact on the patient's volume and hemodynamic status. During the early days of hemodialysis, low dialysate sodium concentrations were routinely used to help decrease volume overload and hypertension. However, a low dialysate sodium during a 3 to 4 hour hemodialysis session acutely decreases the intravascular volume over a short period of time as the result of the net negative sodium balance that is produced by diffusion. This approach can cause significant hypotension and discomfort in the form of nausea, vomiting, muscle cramping, fatigue, and dizziness.",
"   </p>",
"   <p>",
"    Since the early 1980s, high-sodium bicarbonate-based dialysate has mostly eliminated hypotension and discomfort during hemodialysis. However, the widespread use of these high-sodium solutions has caused dialysis salt loading with resultant postdialysis thirst, interdialytic weight gain, and hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/8\">",
"     8",
"    </a>",
"    ]. The problem of postdialytic weight gain and hypertension is mostly seen in the chronic hemodialysis population, but can also have bearing in the acute setting, particularly in patients with an intact thirst mechanism and the ability to drink fluid based on their thirst.",
"   </p>",
"   <p>",
"    During acute intermittent hemodialysis, particularly in the ICU setting, hypotension is common since patients usually have compromised hemodynamic factors due to cardiac, hepatic, infectious, or bleeding complications. The hypotension that can develop during maximal rates of solute removal often compromises clearance and ultrafiltration targets.",
"   </p>",
"   <p>",
"    To avoid hemodynamic instability during acute intermittent hemodialysis, sodium modeling can be administered by utilizing a higher dialysate sodium concentration at the beginning of hemodialysis and progressively decreasing it throughout the session to avoid lowering the plasma osmolarity abruptly.",
"   </p>",
"   <p>",
"    A concise mechanism describing sodium profiling is best described by the following quotation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    \"A high dialysate sodium concentration is used initially with a progressive reduction toward isotonic or hypotonic levels by the end of the procedure. This method allows for a diffusive sodium influx early in the session to prevent the rapid decline in plasma osmolality resulting from the efflux of urea and other small molecular weight solutes. During the remainder of the procedure, when the reduction in osmolality accompanying urea removal is less abrupt, the lower dialysate sodium level minimizes the development of hypertonicity and any resultant excessive thirst, fluid gain, and hypertension in the interdialytic period.\"",
"   </p>",
"   <p>",
"    Although sodium modeling has been studied mostly in the chronic hemodialysis population, a randomized, cross-over study of 10 patients evaluated sodium modeling in acute renal failure patients in the ICU [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/10\">",
"     10",
"    </a>",
"    ]. The study used either a fixed dialysate sodium regimen (140",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    with a fixed ultrafiltration (UF) rate spread over the entire dialysis time, or a variable dialysate sodium profile which varied dialysate sodium (160",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    to 140",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    in a stepwise fashion. The group's UF profile was varied in a similar fashion to the sodium profiling prescription (half of the fluid being removed during the first third of the treatment, and the remaining half over the last two thirds).",
"   </p>",
"   <p>",
"    The following results were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sodium modeling with variable UF rate was associated with greater hemodynamic stability compared to the fixed regimen.",
"     </li>",
"     <li>",
"      Significantly less frequent interventions involving nursing and volume replacement was noted in the sodium modeling and variable UF rate arm.",
"     </li>",
"     <li>",
"      Relative blood volume changes were less during sodium modeling.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The group concluded that sodium and ultrafiltration profiling may be the preferred dialysis prescription for ARF patients in the ICU at risk for hemodynamic instability while undergoing intermittent hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several sodium modeling prescriptions exist. Multiple sodium modeling prescriptions are programmed in most hemodialysis machines. Patients may respond to only one or all available prescriptions. Thus, trials are required to find the best sodium modeling prescription in ARF patients on hemodialysis.",
"   </p>",
"   <p>",
"    The same sodium modeling principles used for intradialytic hypotension in the chronic hemodialysis population can also be used in ARF patients. We recommend using combined sodium and UF profiling if hypotension occurs while on intermittent hemodialysis (IHD) in the acute setting.",
"   </p>",
"   <p>",
"    We prefer either of the following two specific strategies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With one",
"      <span class=\"nowrap\">",
"       high/low",
"      </span>",
"      sodium modeling prescription, a high dialysate sodium (eg, 150",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      alternates with a low dialysate sodium (eg, 130",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      with each level set for an equal amount of time. The average of the",
"      <span class=\"nowrap\">",
"       high/low",
"      </span>",
"      sodium levels (eg, 140",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      is the dialysate sodium usually prescribed in hemodynamically stable patients with normal serum sodium levels. During the low sodium period, the ultrafiltration rate is minimized or stopped. Ultrafiltration only occurs during the high sodium period to draw out intracellular water due to the extracellular hypernatremia.",
"     </li>",
"     <li>",
"      Another sodium modeling prescription is to set the initial dialysate sodium at a high level (eg, 150 to 160",
"      <span class=\"nowrap\">",
"       meq/L).",
"      </span>",
"      Subsequently, the dialysate sodium level is then decreased in stepwise, exponential or linear decrements (depending on clinical effect) to a final low level (eg, 140",
"      <span class=\"nowrap\">",
"       meq/L).",
"      </span>",
"      To maintain isonatremia, the time average concentration of dialysate sodium should be the same or marginally lower than the pre-dialysis serum sodium concentration (approximately within 1.0 to 2.0",
"      <span class=\"nowrap\">",
"       meq/L).",
"      </span>",
"      With a linear sodium profile, for example, the duration (and degree) of dialysis spent below the isonatremic concentration must be approximately equal to that spent above it [",
"      <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other methods to treat hypotension are reviewed below. Since lower blood flows through the dialyzer may result in less hemodynamic instability, sustained low efficiency hemodialysis (SLED) over 6 to 12 hours or continuous renal replacement therapy (CRRT) can be used if sodium modeling on IHD does not improve the blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33530?source=see_link\">",
"     \"Sustained low efficiency or extended daily dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dialysate sodium concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of dialysate sodium concentration depends upon the predialysis serum sodium concentration, hemodynamic status, the diffusion gradient for sodium, method of serum sodium measurement, and Gibbs-Donnan effect. Issues surrounding dialysate sodium concentration in patients with dysnatremias or hemodynamic instability are discussed in the next and previous sections, respectively. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Dysnatremias'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11\">",
"     'Sodium modeling and hemodialysis hypotension'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    With respect to the additional factors that affect the choice of the dialysate sodium concentration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diffusion gradient for sodium lies between its ionic activity in dialysate and blood water [",
"      <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/8,12\">",
"       8,12",
"      </a>",
"      ]. Since laboratories use a variety of methods to measure serum sodium concentration (flame photometry, indirect ionometry and direct ionometry), there is a subtly different relationship between the gradient and sodium ionic activity for each method used.",
"     </li>",
"     <li>",
"      The Gibbs-Donnan effect denotes the reduced sieving coefficient of the dialysis membrane for sodium that arises as a result of negatively charged plasma proteins [",
"      <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result of all of these factors, a high sodium dialysate for the majority of patients would be characterized by a sodium concentration of approximately 141",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    and a low sodium dialysate by a sodium concentration of approximately 137",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    For individual patients, the dialysate sodium concentration that results in no net transfer of sodium has been estimated in various studies to be between 0.1 to 3.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    below that of the pre-dialysis serum sodium concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/11,14-16\">",
"     11,14-16",
"    </a>",
"    ]. For most patients with normal or near-normal serum sodium levels, we use a sodium dialysate concentration of approximately 137",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Dysnatremias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid correction of an abnormal serum sodium concentration should be",
"    <strong>",
"     avoided",
"    </strong>",
"    during dialysis to avoid neurologic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/17\">",
"     17",
"    </a>",
"    ]. Failure to adjust the dialysis prescription may lead to cerebral edema in the patient with severe chronic hypernatremia and osmotic demyelination (pontine and extrapontine myelinolysis) in the patient with severe chronic hyponatremia. Although uremia may provide some protection against osmotic demyelination, case reports of this complication following dialysis of severely hyponatremic patients lead us to recommend a cautious approach in most patients.",
"   </p>",
"   <p>",
"    The overall dialysis strategy for the management of dysnatremias is the same as that in the non-dialysis general population. Large, rapid changes in the serum sodium concentration are very rarely indicated.",
"   </p>",
"   <p>",
"    Only patients with hyperacute salt poisoning (eg, due to the suicidal ingestion of sodium chloride or the inadvertent intravenous infusion of hypertonic saline during a therapeutic abortion) or hyperacute water intoxication (eg, as a complication of marathon running or use of the drug, \"Ecstasy\") should ever be allowed to undergo aggressive initial correction of their serum sodium concentration. In such patients with hyponatremia, for example, aggressive initial correction at a rate of 1.5 to 2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    per hour, may be indicated for the first three to four hours or until the symptoms resolve. However, the plasma sodium concentration should probably be raised by less than 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in the first 24 hours and less than 18",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in the first 48 hours. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the treatment of hyponatremia\", section on 'Rate of correction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the vast majority of patients with more chronic dysnatremias, the treatment during a single dialysis session should be adjusted to provide a rate of correction that does not exceed the generally recommended rate. If the serum sodium concentration is very high or very low, it may be impractical to avoid a rapid change solely by adjusting the dialysate sodium concentration. In many such patients, it may be necessary to either cut the dialysis session short or to offset the effect of dialysis by concurrent infusions of hypertonic saline or D5W. Hourly measurements of the serum sodium concentration during the course of dialysis are mandatory.",
"   </p>",
"   <p>",
"    Another possibility is to use continuous renal replacement therapy. This modality is far less efficient at changing serum sodium concentrations, which may therefore change more slowly than with the use of intermittent hemodialysis.",
"   </p>",
"   <p>",
"    Some authorities also favor the following approach [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with severe chronic hyponatremia (predialysis serum sodium level less than 130",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      a cautious strategy is to set the dialysate sodium concentration at a level that is no higher than 15 to 20",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      above the plasma level of the patient [",
"      <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/18\">",
"       18",
"      </a>",
"      ]. The goal would be correction of the hyponatremia only after multiple hemodialysis sessions that are performed over a period of several days.",
"     </li>",
"     <li>",
"      In those with hypernatremia, the use of dialysate sodium concentrations more than 3 to 5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      below the plasma sodium concentration is associated with hypotension, muscle cramps, and most importantly disequilibrium syndrome. Thus, a reasonable and safe approach would be to use a dialysate sodium concentration within 2",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      of the plasma sodium concentration in the first dialysis session. Subsequently, correction of the hypernatremia could be performed with the administration of hypotonic solutions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24393?source=see_link\">",
"       \"Treatment of hypernatremia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Buffer solutions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acetate was the predominant buffer used during the early days of hemodialysis. However, acetate is presently not routinely used because of associated cardiac and hemodynamic instability.",
"   </p>",
"   <p>",
"    The main dialysate buffer currently used in IHD is bicarbonate. This buffer is inexpensive and generally well tolerated without the hemodynamic problems seen with acetate.",
"   </p>",
"   <p>",
"    The main disadvantage of bicarbonate is that it precipitates as an insoluble salt when stored together with divalent cations calcium and magnesium, thereby requiring the buffer and electrolytes to be stored separately prior to hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, possible side effects with bicarbonate include hypoxemia due to decrease respiratory drive with higher pH, and altered mental status, weakness, cramping, and lethargy due to acute metabolic alkalosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dialysate bicarbonate concentration should vary based upon the acid-base status of the patient. The usual dialysate bicarbonate concentration in chronic hemodialysis is approximately 33 to 35",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    We suggest that this high concentration bicarbonate solution be used in cases of moderate metabolic acidosis in ARF. In severe metabolic acidosis, the concentration of the bicarbonate solution may be maximized (eg, 40",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    and extended duration of hemodialysis may be necessary. In addition, in patients being mechanically ventilated using low-tidal volume ventilation, an increased dialysate bicarbonate concentration may be required to compensate for the respiratory acidosis resulting from \"permissive hypercapnea.\" In contrast, in patients being mechanically hyperventilated to compensate for metabolic acidosis, the minute ventilation (respiratory rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tidal volume) may need to be reduced to avoid severe alkalemia as the metabolic acidosis is corrected with dialysis.",
"   </p>",
"   <p>",
"    Acute hemodialysis patients can also be alkalemic. The severity of the alkalemia and the process generating the alkalosis are the main issues to help determine the optimal dialysate bicarbonate concentration. In particular, the clinician must investigate whether there is on-going generation versus a one-time insult causing the alkalosis. A one-time insult can be resolved with a single hemodialysis treatment, whereas on-going generation of alkalosis may require frequent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    long hemodialysis sessions with a lower bicarbonate dialysate.",
"   </p>",
"   <p>",
"    If the predialysis serum bicarbonate level is above 28",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or respiratory alkalosis is present, the usual dialysate bicarbonate concentration should not be used [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/21\">",
"     21",
"    </a>",
"    ]. In this setting, a lower bicarbonate dialysis concentration would be appropriate.",
"   </p>",
"   <p>",
"    Modern machines can adjust dialysate bicarbonate in 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    increments (from 40 to 20",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"    In addition, the frequency and duration of the dialysis treatment(s) as well as the volume of ultrafiltrate must all be considered when determining the specific concentration of bicarbonate in the dialysate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;In chronic hemodialysis patients, the standard dialysate calcium concentration is 2.5",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    In addition to helping manage secondary hyperparathyroidism, this level is used to avoid the development of hypercalcemia and elevated calcium-phosphorus product that can occur with higher dialysate calcium concentrations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the acute hemodialysis setting, the dialysate calcium concentration may be chosen to treat the presence of either hypo- or hypercalcemia. According to some authorities, the dialysate calcium concentration for acute hemodialysis should be 3.0 to 3.5",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    and the routine use of the standard concentration for chronic hemodialysis is inappropriate considering the risk of developing hypocalcemia in the acute setting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, a higher dialysate calcium concentration used in the setting of predialysis hypocalcemia may prevent further worsening of hypocalcemia with the correction of acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A higher dialysate calcium concentration can also improve intradialytic hypotension by improving cardiac performance. As an example, one prospective crossover study compared the effect of high dialysate calcium concentration (3.5",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    with low dialysate calcium concentration (2.5",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    on hemodynamic stability in patients on IHD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/22\">",
"     22",
"    </a>",
"    ]. The study patients had a history of intradialytic hypotension and were also administered therapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    , cool dialysate, or a combination of these two therapies.",
"   </p>",
"   <p>",
"    Compared with low-dialysate calcium, the following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High-dialysate calcium significantly increased post-hemodialysis mean arterial pressure (MAP).",
"     </li>",
"     <li>",
"      High-dialysate calcium improved the lowest intradialytic MAP, but was not statistically significant.",
"     </li>",
"     <li>",
"      The improvements in blood pressure with high-dialysate calcium were not associated with similar reductions in symptoms or interventions for intradialytic hypotension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypocalcemia is fairly common in ICU patients, particularly those with sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/23\">",
"     23",
"    </a>",
"    ]. This combination is reportedly associated with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This observation has led some to postulate that treatment of hypocalcemia in those with sepsis may improve outcomes. However, calcium administration to rodents with sepsis appears to be harmful [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Its administration may therefore be associated with higher mortality in critically ill patients with sepsis. Thus, administering calcium to treat hemodynamic instability during acute intermittent hemodialysis may be harmful to septic patients and should be considered carefully. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since total plasma calcium levels are poorly predictive of the ionized level, the ionized plasma calcium level should be measured prior to hemodialysis in acutely ill patients with significant hypocalcemia or hypercalcemia. This is particularly important since acute phase responses (eg, sepsis) and changes in pH during dialysis and mechanical ventilation can affect ionized calcium levels independent of the total plasma calcium concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23685?source=see_link\">",
"     \"Relation between total and ionized serum calcium concentration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest the following concerning the dialysate calcium concentration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We favor adjusting the dialysate calcium concentration to avoid hypercalcemia or clinical hypocalcemia. If the measured total plasma calcium level is used in this setting (although ionized plasma calcium is preferred), it is important that this level is corrected based upon the serum albumin level and other factors given that the total plasma calcium concentration will change in parallel to the albumin concentration. This issue and the correction formula is discussed separately (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23685?source=see_link\">",
"       \"Relation between total and ionized serum calcium concentration\"",
"      </a>",
"      ). We use a dialysate calcium concentration of 3.0 to 3.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in the patient with significant hypocalcemia (total plasma calcium level &lt;8.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [&lt;2.0",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      particularly if the patient is symptomatic. If the patient has severe hypercalcemia (total plasma calcium level &gt;12.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [&gt;3.0",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      we use a dialysate calcium concentration of 2.0 to 2.5",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      For patients with mild hypocalcemia, normocalcemia, or mild hypercalcemia (total plasma calcium level between 8.0 to 12.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.0 to 3.0",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      we use a dialysate calcium concentration of 2.5",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"     </li>",
"     <li>",
"      To treat intradialytic hypotension, increasing the dialysate calcium may be used in combination with sodium profiling and a lower dialysate temperature. We do not use a dialysate calcium concentration above 3.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      for this purpose. The development of hypercalcemia must be avoided with this strategy. However, the ideal level of ionized calcium in critically ill patients is not known, and may not be the same as in normal subjects. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Ultrafiltration and blood pressure control'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H12\">",
"       'Dialysate sodium concentration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     BLOOD FLOW RATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deciding upon the optimal blood flow rate through the dialyzer is determined by various factors. For patients with chronic kidney disease who are initiated on hemodialysis, the blood flow rate is increased incrementally over several sessions to avoid the rapid removal of accumulated blood solutes that can lead to the development of the dialysis disequilibrium syndrome and to evaluate the angioaccess. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13125?source=see_link\">",
"     \"Dialysis disequilibrium syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With ARF, blood solutes have usually not had time to accumulate to the degree observed in the ESRD population. However, if the BUN has been &gt;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    for at least three days in the patient with ARF, there may be enough osmole accumulation in the CNS to justify a slow removal for the first and second dialysis sessions. Thus, lower blood flow rates should be prescribed at the initiation of therapy in such patients. When this is not necessary, high blood flow rates can be initiated at the onset of acute IHD without fear of precipitating the disequilibrium syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13125?source=see_link\">",
"     \"Dialysis disequilibrium syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Blood flow rate in acute hemodialysis is dependent upon temporary dialysis catheter performance, length, and location. Dialysis catheters must be long enough to reach either the superior vena cava (SVC) or inferior vena cava, where the venous blood flows are the highest. Left-sided internal jugular (IJ) and subclavian catheters tend to provide unreliable blood flow, at a rate that is typically up to 100",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    lower than elsewhere because their tips abut the walls of either the SVC or innominate vein [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/27\">",
"     27",
"    </a>",
"    ]. The best blood flows are attained with femoral vein and right-sided IJ catheters. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=see_link\">",
"     \"Overview of central catheters for acute and chronic hemodialysis access\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Higher blood flows are necessary during IHD to provide sufficient overall solute clearance because of the relatively shorter duration of the session, whereas lower blood flows are sufficient to achieve adequate clearance by CRRT due to its continuous nature [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/27\">",
"     27",
"    </a>",
"    ]. However, the use of higher blood flows with IHD may result in rapid reduction in serum osmolality promoting water movement into cells, thus reducing effective circulating volume. This may exacerbate intradialytic hypotension despite measures to treat intradialytic hypotension, particularly in critically ill patients suffering from septic shock, cardiac decompensation, bleeding, or hepatic insufficiency. Non-compliant dialyzers, smaller surface area dialyzers, and ultrafiltration control minimize the need to decrease blood flow rate.",
"   </p>",
"   <p>",
"    We use a dialysis blood flow rate of 400 mL per minute. If a lower blood flow (or lower ultrafiltration rate) is required because of hemodynamic instability due to rapid osmolar shifts, the best dialysis modality is unclear. Until further data are available, we suggest slower solute removal over six to 12 hours by sustained low-efficiency dialysis (SLED) or by continuous renal replacement therapy (CRRT). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28295?source=see_link\">",
"     \"Continuous renal replacement therapy in acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link&amp;anchor=H9#H9\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\", section on 'CRRT versus intermittent hemodialysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIALYSATE TEMPERATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasoconstriction due to lower body temperatures has been used to increase vascular resistance and improve hemodynamic stability during IHD in ESRD. Cool temperature dialysate typically uses a temperature of 35.0 degrees Celsius, which may be associated with symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24690?source=see_link\">",
"     \"Cool temperature hemodialysis: Hemodynamic effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypothermia, however, may be undesirable in critically ill patients due to adverse effects upon myocardial function, end-organ perfusion, blood clotting, and possibly renal recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/28\">",
"     28",
"    </a>",
"    ]. With blood temperature monitoring, the patients' blood temperature is maintained precisely at target value by a series of feedback loops controlling thermal transfer to and from the dialysate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/29\">",
"     29",
"    </a>",
"    ]. It is effective in ameliorating hemodynamic instability for ESRD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood temperature monitoring might conceivably allow for controlled cooling in critically ill ARF patients without the risk of hypothermic damage. However, it has not been evaluated in this setting. Our recommendations concerning the use of cold temperature hemodialysis are presented in the next section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ULTRAFILTRATION AND BLOOD PRESSURE CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining optimal ultrafiltration (UF) requirements in critically ill ARF patients is challenging. This is determined in part by physical examination, laboratory values, and hemodynamic indices. In general, no one specific test or parameter is sufficient in isolation.",
"   </p>",
"   <p>",
"    The following two over-riding principles should be recognized:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The target weight in ESRD patients undergoing chronic maintenance dialysis is usually determined empirically as the weight at which clinical signs of extracellular fluid expansion are absent, and below which clinical signs of extracellular depletion arise. In contrast, extracellular volume status in critically ill ARF patients is not necessarily an end-point itself. The volume expansion that is frequently observed in such patients is often necessary to maintain optimal circulatory and oxygen transport status.",
"     </li>",
"     <li>",
"      The clinician should appreciate that the relationship between blood volume and hypotension is different in patients with ESRD and critically ill individuals with ARF. Autonomic function and circulating humoral agents all mediate and mitigate this relationship, and these factors are not comparable between the two groups. This can be illustrated by considering blood volume monitoring, which is a biofeedback system that automatically adjusts ultrafiltration rate and dialysate sodium content in response to a fall in circulating intravascular volume. Although these systems can convincingly reduce the occurrence of intradialytic hypotension in ESRD patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/31\">",
"       31",
"      </a>",
"      ], they are ineffective for ameliorating hypotension in critically ill ARF patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/32\">",
"       32",
"      </a>",
"      ]. This lack of a predictable relationship between volume status and hemodynamic stability means that UF goals for a given patient should be assessed not only in terms of fluid mass balance or the mandatory removal of obligatory fluid loads, but also in terms of the effect of intervention on the patient's broader clinical condition and hemodynamic status",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In hemodynamically stable patients, the estimation of target intravascular volume can be made in the usual fashion utilized for ESRD patients. However, in hemodynamically unstable patients, target intravascular volume should be titrated to invasive or non-invasive (bio-impedance analysis, pulse contour analysis [PiCCO], or echocardiography) monitoring, which should guide the UF goals for a given IHD session.",
"   </p>",
"   <p>",
"    Ultrafiltration during IHD can result in significant intradialytic hypotension, which can be treated by reducing or discontinuing ultrafiltration,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a reducing the blood flow rate. In addition to these maneuvers, modifying other dialysis-dependent factors of intradialytic hypotension (eg, cooling dialysate temperature and improving autonomic reflexes) can help deliver effective hemodialysis while optimizing ultrafiltration and hemodynamic tolerance.",
"   </p>",
"   <p>",
"    In order of efficacy, the following measures help prevent intradialytic hypotension during IHD in ARF:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Minimize UF rate requirements by increasing frequency of treatments",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increased duration of treatments",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Sodium/ultrafiltration",
"      </span>",
"      profiling",
"     </li>",
"     <li>",
"      Cool temperature dialysate",
"     </li>",
"     <li>",
"      Higher dialysate calcium concentration",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"       Midodrine",
"      </a>",
"      (alpha-1 adrenergic agonist used in autonomic dysfunction), which may be administered in the absence of more powerful pharmacologic forms of pressor support.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further discussion concerning intradialytic hypotension in patients undergoing chronic intermittent hemodialysis can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=see_link\">",
"     \"Hemodynamic instability during hemodialysis: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend initially treating intradialytic hypotension with the first three measures listed above. In addition to these interventions, normal saline intravenous boluses given during hemodialysis can transiently increase blood pressure.",
"   </p>",
"   <p>",
"    Despite the above-mentioned measures, hemodynamic instability may still occur because of the various dialysis-independent causes of intradialytic hypotension present in the acute setting (eg, cardiogenic, vasodilatory, or hypovolemic shock). If measures to improve hemodynamic stability during IHD sessions are not successful, switching to SLED or CRRT usually improves hemodynamics while maintaining an acceptable rate of ultrafiltration and solute clearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues surrounding anticoagulation in patients undergoing acute hemodialysis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38120?source=see_link\">",
"     \"Hemodialysis anticoagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PRE- AND POSTHEMODIALYSIS LABORATORY VALUE MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific laboratory values are usually required either before or after an acute hemodialysis session. A predialysis basic metabolic profile should be reviewed prior to some acute hemodialysis sessions since electrolyte and",
"    <span class=\"nowrap\">",
"     acid/base",
"    </span>",
"    status can profoundly change between treatments and require alterations to the dialysate bath.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Drug monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic drug monitoring levels can be measured post-hemodialysis to help guide supplemental dosing. The following equation can be used to calculate the supplemental dose that takes the patient from the measured level to the desired peak level of drug [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp; Supplemental dose = Vd * IBW * (Desired Peak Level - Measured Level)",
"   </p>",
"   <p>",
"    where Vd is the volume of distribution of the drug and IBW is the ideal body weight.",
"   </p>",
"   <p>",
"    As an example, a patient with an ideal body weight of 70 kg is receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , with the vancomycin Vd 0.75, and the measured vancomycin level of 12",
"    <span class=\"nowrap\">",
"     mg/L.",
"    </span>",
"    The desired vancomycin peak level in this case is 30",
"    <span class=\"nowrap\">",
"     mg/L.",
"    </span>",
"    The calculated supplemental dose of vancomycin would be 945 mg after hemodialysis to achieve a peak level of 30",
"    <span class=\"nowrap\">",
"     mg/L.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIALYSIS DOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis dose in acute renal failure is increasingly recognized as an important issue. This is briefly reviewed in this section, and in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The delivered IHD dose tends to be low in critically ill ARF patients, and lower than that prescribed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. There have been some studies showing a relationship between acute IHD dose and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?9/26/9642/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. However, as described elsewhere in UpToDate, the",
"    <span class=\"nowrap\">",
"     VA/NIH",
"    </span>",
"    Acute Renal Failure Trial Network (ATN) study did not find a difference in mortality associated with a more intensive dosing strategy for renal replacement therapy.",
"   </p>",
"   <p>",
"    Based on the results of the ATN study, we recommend that intermittent hemodialysis be provided three times per week with monitoring of the delivered dose of therapy to ensure a minimum delivered",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 1.2 per treatment. There is no evidence that more frequent hemodialysis is associated with improved outcomes unless necessitated for specific indications (eg, hyperkalemia, volume excess, hypotension, etc). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=see_link\">",
"       \"Patient information: Hemodialysis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=see_link\">",
"       \"Patient information: Hemodialysis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indications for renal replacement therapy (RRT) in patients with acute renal failure (ARF) generally include volume overload refractory to diuretics, hyperkalemia, metabolic acidosis, uremia, and toxic overdose of a dialyzable drug. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"       \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Once the decision to initiate RRT has been made, the specific modality of dialytic support must be chosen. This includes peritoneal dialysis or hemodialysis and its variations (eg, hemofiltration), and the acute dialysis prescription determined. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Modality'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28295?source=see_link\">",
"       \"Continuous renal replacement therapy in acute kidney injury (acute renal failure)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When acute hemodialysis is chosen as the dialytic support modality, vascular access must be established prior to initiating treatment. Placement of the venous dialysis catheter must be considered carefully. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Vascular access'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=see_link\">",
"       \"Overview of central catheters for acute and chronic hemodialysis access\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the setting of ARF, the optimal choice of artificial dialysis membrane is unclear. We suggest that biocompatible dialysis membranes be used in this setting. If the water system is of high quality, high flux biocompatible dialysis membranes should be used. By comparison, low flux biocompatible dialysis membranes or a prefilter added to the dialysis machine should be used if the water system is not of high quality. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hemodialyzer membranes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The dialysate solution composition consists of potassium, sodium, bicarbonate buffer, calcium, magnesium, chloride, and glucose. The dialysate composition in acute hemodialysis is routinely altered each treatment to correct the metabolic abnormalities that can rapidly develop during ARF. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Dialysate composition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is not a standard or fixed dialysate potassium concentration in the acute hemodialysis prescription because of wide variability in the serum potassium level prior to initiating the hemodialysis session. The typical potassium concentration in the dialysate for acute hemodialysis ranges from 2.0 to 4.0",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      The dialysate bath potassium is determined by both the absolute predialysis serum potassium and the rate of rise in the inter-dialytic period. A rapid rate of rise of the serum potassium may best be treated by daily hemodialysis rather than lowering the dialysate potassium bath concentration. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Dialysate potassium concentration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The hemodialysis treatment can provoke ventricular arrhythmias, which are related to dialysis-induced reductions in the serum potassium. They are independently associated with numerous risk factors such as coronary artery disease, left ventricular hypertrophy (LVH),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      use, systolic blood pressure, and advanced age. We therefore recommend that patients with underlying cardiac disorders who undergo acute hemodialysis should be placed on a cardiac rhythm monitor during the dialysis session. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Complications with potassium removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of the dialysate sodium concentration can have a significant impact on the patient's volume and hemodynamic status. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Sodium modeling and hemodialysis hypotension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The dialysate bicarbonate concentration should vary based upon the acid-base status of the patient. The usual dialysate bicarbonate concentration in chronic hemodialysis is approximately 33 to 35",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      We recommend that this high concentration bicarbonate solution be used in cases of moderate metabolic acidosis in ARF. In severe metabolic acidosis, the concentration may be maximized (eg, 40",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      and extended duration of hemodialysis may be necessary. Acute hemodialysis patients can also be alkalotic. The severity of the alkalosis and the process generating the alkalosis are the main issues to help determine the optimal dialysate bicarbonate concentration. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Buffer solutions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend adjusting the dialysate calcium concentration to avoid hypercalcemia or clinical hypocalcemia. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Calcium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We use a dialysis blood flow rate of 400 mL per minute. If a lower blood flow rate is required because of hemodynamic instability due to rapid osmolar shifts, the best dialysis modality is unclear and the subject of ongoing study. Until further data are available, we suggest slower solute removal over six to 12 hours by sustained low-efficiency dialysis (SLED) or by continuous renal replacement therapy (CRRT). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Blood flow rate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Determining the ultrafiltration goals in ARF patients can be challenging. The estimation of target intravascular volume will guide the ultrafiltration goals for a given intermittent hemodialysis session. Ultrafiltration during IHD can result in significant intradialytic hypotension. This can be treated by minimizing UF rate requirements by increasing frequency of treatments",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increased duration of treatments, as well as",
"      <span class=\"nowrap\">",
"       sodium/ultrafiltration",
"      </span>",
"      profiling, and using cool temperature dialysate. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Ultrafiltration and blood pressure control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that intermittent hemodialysis be provided at least three-times per week (alternate days) with monitoring of the delivered dose of dialysis to ensure delivery of a",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      of at least 1.2 per treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Dialysis dose'",
"      </a>",
"      above.) However, more frequent dialysis may be necessary for specific clinical scenarios, such as intractable hyperkalemia, volume overload, or severe hypotension.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Marshall, MR, Golper, TA. Intermittent Hemodialysis in Intensive Care in Nephrology, Murray, P, Brady, H, Hall, J (Eds), Taylor &amp; Francis, Oxford 2005.",
"    </li>",
"    <li>",
"     Daugirdas, JT, Blake, et al. Handbook of dialysis, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/3\">",
"      Zehnder C, Gutzwiller JP, Huber A, et al. Low-potassium and glucose-free dialysis maintains urea but enhances potassium removal. Nephrol Dial Transplant 2001; 16:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/4\">",
"      Hou S, McElroy PA, Nootens J, Beach M. Safety and efficacy of low-potassium dialysate. Am J Kidney Dis 1989; 13:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/5\">",
"      Ward RA, Wathen RL, Williams TE, Harding GB. Hemodialysate composition and intradialytic metabolic, acid-base and potassium changes. Kidney Int 1987; 32:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/6\">",
"      Ahmed J, Weisberg LS. Hyperkalemia in dialysis patients. Semin Dial 2001; 14:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/7\">",
"      Morrison G, Michelson EL, Brown S, Morganroth J. Mechanism and prevention of cardiac arrhythmias in chronic hemodialysis patients. Kidney Int 1980; 17:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/8\">",
"      Flanigan M. Dialysate composition and hemodialysis hypertension. Semin Dial 2004; 17:279.",
"     </a>",
"    </li>",
"    <li>",
"     Henrich, WL. Principles and practice of dialysis, 3rd ed, Lippincott Williams &amp; Wilkins, 2004. p.696.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/10\">",
"      Paganini EP, Sandy D, Moreno L, et al. The effect of sodium and ultrafiltration modelling on plasma volume changes and haemodynamic stability in intensive care patients receiving haemodialysis for acute renal failure: a prospective, stratified, randomized, cross-over study. Nephrol Dial Transplant 1996; 11 Suppl 8:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/11\">",
"      Song JH, Lee SW, Suh CK, Kim MJ. Time-averaged concentration of dialysate sodium relates with sodium load and interdialytic weight gain during sodium-profiling hemodialysis. Am J Kidney Dis 2002; 40:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/12\">",
"      Kooman JP, van der Sande F, Leunissen K, Locatelli F. Sodium balance in hemodialysis therapy. Semin Dial 2003; 16:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/13\">",
"      Locatelli, F, Di Filippo, S, Manzoni, C. Sodium kinetics during dialysis. Semin Dial Suppl 1999; 12:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/14\">",
"      Locatelli F, Ponti R, Pedrini L, et al. Sodium kinetics across dialysis membranes. Nephron 1984; 38:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/15\">",
"      Gotch FA, Evans MC, Keen ML. Measurement of the effective dialyzer Na diffusion gradient in vitro and in vivo. Trans Am Soc Artif Intern Organs 1985; 31:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/16\">",
"      Flanigan MJ, Khairullah QT, Lim VS. Dialysate sodium delivery can alter chronic blood pressure management. Am J Kidney Dis 1997; 29:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/17\">",
"      Oo TN, Smith CL, Swan SK. Does uremia protect against the demyelination associated with correction of hyponatremia during hemodialysis? A case report and literature review. Semin Dial 2003; 16:68.",
"     </a>",
"    </li>",
"    <li>",
"     Daugirdas, JT, Ross, et al. Acute hemodialysis Prescription. In: Handbook of Dialysis, Daugirdas, JT, Blake, PG, Ing, SA (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/19\">",
"      Bra&uuml;se M, Deppe CE, Hollenbeck M, et al. Congestive heart failure as an indication for continuous renal replacement therapy. Kidney Int Suppl 1999; :S95.",
"     </a>",
"    </li>",
"    <li>",
"     Henrich, WL. Principles and practice of dialysis. 3rd ed, Lippincott Williams &amp; Wilkins, 2004. p. 696.",
"    </li>",
"    <li>",
"     Daugirdas, JT, et al. Handbook of Dialysis, Lippincott Williams &amp; Wilkins, Philadelphia 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/22\">",
"      Alappan R, Cruz D, Abu-Alfa AK, et al. Treatment of Severe Intradialytic Hypotension With the Addition of High Dialysate Calcium Concentration to Midodrine and/or Cool Dialysate. Am J Kidney Dis 2001; 37:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/23\">",
"      Zaloga GP, Chernow B, Cook D, et al. Assessment of calcium homeostasis in the critically ill surgical patient. The diagnostic pitfalls of the McLean-Hastings nomogram. Ann Surg 1985; 202:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/24\">",
"      Zaloga GP, Chernow B. The multifactorial basis for hypocalcemia during sepsis. Studies of the parathyroid hormone-vitamin D axis. Ann Intern Med 1987; 107:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/25\">",
"      Malcolm DS, Zaloga GP, Holaday JW. Calcium administration increases the mortality of endotoxic shock in rats. Crit Care Med 1989; 17:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/26\">",
"      Zaloga GP, Sager A, Black KW, Prielipp R. Low dose calcium administration increases mortality during septic peritonitis in rats. Circ Shock 1992; 37:226.",
"     </a>",
"    </li>",
"    <li>",
"     Marshall, MR, Golper, TA. Intermittent Hemodialysis in Intensive Care in Nephrology, Murray, P, Brady, H, Hall, J (Eds), Taylor &amp; Francis, Oxford, UK 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/28\">",
"      Zager RA, Gmur DJ, Bredl CR, Eng MJ. Temperature effects on ischemic and hypoxic renal proximal tubular injury. Lab Invest 1991; 64:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/29\">",
"      Schneditz D. Temperature and thermal balance in hemodialysis. Semin Dial 2001; 14:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/30\">",
"      Maggiore Q, Pizzarelli F, Santoro A, et al. The effects of control of thermal balance on vascular stability in hemodialysis patients: results of the European randomized clinical trial. Am J Kidney Dis 2002; 40:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/31\">",
"      Santoro A, Mancini E, Basile C, et al. Blood volume controlled hemodialysis in hypotension-prone patients: a randomized, multicenter controlled trial. Kidney Int 2002; 62:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/32\">",
"      Tonelli M, Astephen P, Andreou P, et al. Blood volume monitoring in intermittent hemodialysis for acute renal failure. Kidney Int 2002; 62:1075.",
"     </a>",
"    </li>",
"    <li>",
"     Aronoff, GR, et al. Drug prescribing in renal failure: dosing guidelines for adults, 4th ed, American College of Physicians, Philadelphia 1999. p.176.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/34\">",
"      Evanson JA, Himmelfarb J, Wingard R, et al. Prescribed versus delivered dialysis in acute renal failure patients. Am J Kidney Dis 1998; 32:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/35\">",
"      American Society of Nephrology 30th annual meeting. San Antonio, Texas, November 2-5, 1997. Abstracts. J Am Soc Nephrol 1997; 8:1A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/36\">",
"      Paganini, EP. Establishing a dialysis therapy/patient outcome link in intensive care unit acute dialysis for patients with acute renal failure. Am J Kidney Dis 1996; 28:S81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/26/9642/abstract/37\">",
"      Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002; 346:305.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1854 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-93.125.6.160-7DBF348CA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_26_9642=[""].join("\n");
var outline_f9_26_9642=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MODALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      VASCULAR ACCESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HEMODIALYZER MEMBRANES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIALYSATE COMPOSITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dialysate potassium concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Acute or severe hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Dialysate glucose concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Complications with potassium removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sodium modeling and hemodialysis hypotension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dialysate sodium concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Dysnatremias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Buffer solutions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Calcium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      BLOOD FLOW RATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIALYSATE TEMPERATURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ULTRAFILTRATION AND BLOOD PRESSURE CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PRE- AND POSTHEMODIALYSIS LABORATORY VALUE MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Drug monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIALYSIS DOSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1854\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1854|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?11/50/12068\" title=\"waveform 1\">",
"      EKG peaked T waves in hyperkalemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44069?source=related_link\">",
"      Clinical manifestations of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28295?source=related_link\">",
"      Continuous renal replacement therapy in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24690?source=related_link\">",
"      Cool temperature hemodialysis: Hemodynamic effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13125?source=related_link\">",
"      Dialysis disequilibrium syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38120?source=related_link\">",
"      Hemodialysis anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=related_link\">",
"      Hemodynamic instability during hemodialysis: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10775?source=related_link\">",
"      Maintaining water quality for hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=related_link\">",
"      Overview of central catheters for acute and chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=related_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=related_link\">",
"      Patient information: Hemodialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23685?source=related_link\">",
"      Relation between total and ionized serum calcium concentration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4553?source=related_link\">",
"      Renal and patient outcomes after acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33530?source=related_link\">",
"      Sustained low efficiency or extended daily dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24393?source=related_link\">",
"      Treatment of hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12169?source=related_link\">",
"      Use of peritoneal dialysis for the treatment of acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_26_9643="Red eye treated by primary care";
var content_f9_26_9643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Red eyes that may be managed by the primary care physician",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Stye (hordeoleum)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chalazion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blepharitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subconjunctival hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Conjunctivitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bacterial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Viral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Allergic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Corneal abrasion (urgent follow-up if not better in 24 to 48 hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Corneal foreign body (urgent follow-up if not better in 24 to 48 hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contect lens overwear (urgent follow-up if not better in 24 to 48 hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dry eye syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Episcleritis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_26_9643=[""].join("\n");
var outline_f9_26_9643=null;
var title_f9_26_9644="Duke criteria for IE I";
var content_f9_26_9644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modified Duke criteria for diagnosis of infective endocarditis - table A",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Definite IE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Pathologic criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\">",
"        Microorganism:",
"demonstrated by culture or histology in a vegetation, or in a",
"vegetation that has embolized, or in an intracardiac abscess",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\">",
"        Pathologic lesions: vegetation or intracardiac abscess, confirmed by histology showing active endocarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Clinical criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Using specific definitions listed in",
"        <strong>",
"         Table B:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2 major criteria",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1 major and 3 minor criteria",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        5 minor criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Possible IE*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 major criterion and 1 minor criterion",
"        <strong>",
"         OR",
"        </strong>",
"        3 minor criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Rejected IE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Firm alternate diagnosis for manifestations of endocarditis",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Resolution of manifestations of endocarditis, with antibiotic therapy for four days or less",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        No pathologic evidence of infective endocarditis at surgery or autopsy after antibiotic therapy for four days or less",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Does not meet criteria for possible infective endocarditis, as above",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The category of possible IE represents a modification from the previous published Duke criteria.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Li JS, Sexton DJ, Mick N, et al. Clin Infect Dis 2000; 30:633. Copyright &copy; 2000 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_26_9644=[""].join("\n");
var outline_f9_26_9644=null;
var title_f9_26_9645="Phenytoin interactions with other AEDs";
var content_f9_26_9645=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F55399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F55399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Some interactions between phenytoin and other antiepileptic drugs*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Interacting drugs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effects (probable mechanism)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Phenytoin, with:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Carbamazepine",
"       </td>",
"       <td>",
"        Decreased carbamazepine effect (increased metabolism)",
"       </td>",
"       <td rowspan=\"2\">",
"        Monitor carbamazepine and phenytoin concentrations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Altered phenytoin effect (mechanism not established)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Clonazepam",
"       </td>",
"       <td>",
"        Decreased clonazepam effect (increased metabolism)",
"       </td>",
"       <td>",
"        Monitor clonazepam effect or concentrations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Variable effects on phenytoin concentrations (mechanism not established)",
"       </td>",
"       <td>",
"        Monitor phenytoin concentrations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lamotrigine",
"       </td>",
"       <td>",
"        Decreased lamotrigine serum concentrations (increased metabolism; induction of glucuronidation by phenytoin)",
"       </td>",
"       <td>",
"        Monitor lamotrigine serum concentrations and clinical status; lamotrigine dosage may need to be adjusted",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Oxcarbazepine",
"       </td>",
"       <td>",
"        Possible decreased oxcarbazepine effect (increased metabolism)",
"       </td>",
"       <td>",
"        Monitor clinical status and serum concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Possible phenytoin toxicity with oxcarbazepine doses of 1200 mg/day or higher (decreased metabolism)",
"       </td>",
"       <td>",
"        Monitor phenytoin concentrations especially when oxcarbazepine dosage is 1200 mg/day or higher",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Perampanel",
"       </td>",
"       <td>",
"        Decreased perampanel effect (increased metabolism by CYP3A4)",
"       </td>",
"       <td>",
"        Monitor clinical status; perampanel dosage may need to be adjusted",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tiagabine",
"       </td>",
"       <td>",
"        Decreased tiagabine effect (increased metabolism)",
"       </td>",
"       <td>",
"        Monitor clinical status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Topiramate",
"       </td>",
"       <td>",
"        Possible decreased topiramate effect (increased metabolism)",
"       </td>",
"       <td>",
"        Monitor topiramate concentrations and clinical status; may need to increase topiramate dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Possible phenytoin toxicity (decreased metabolism by CYP2C19)",
"       </td>",
"       <td>",
"        Monitor phenytoin concentrations and clinical status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Valproate",
"       </td>",
"       <td>",
"        Possible phenytoin toxicity (displacement from binding)",
"       </td>",
"       <td>",
"        Monitor phenytoin concentrations and clinical status (unbound concentrations may be more helpful than total)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Possible decreased valproate effect and increased toxicity (increased metabolism and formation of toxic metabolite)",
"       </td>",
"       <td>",
"        Monitor clinical status and valproate serum concentrations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Zonisamide",
"       </td>",
"       <td>",
"        Decreased zonisamide effect (increased metabolism by CYP3A4)",
"       </td>",
"       <td>",
"        Monitor zonisamide concentrations and clinical status; zonisamide dosage may need to be adjusted",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *",
"     <strong>",
"      NOTE: Not all potential interactions are listed.",
"     </strong>",
"     Additional interactions of antiepileptic drugs and management suggestions may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. The Lexi-Interact program can be accessed from the UpToDate new search tab or through the individual drug information topics in the section on Drug interactions.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Drugs for Epilepsy. Treatment guidelines from The Medical Letter 2008; 6(70):37-46. Copyright &copy; 2008 The Medical Letter.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_26_9645=[""].join("\n");
var outline_f9_26_9645=null;
var title_f9_26_9646="Adjuvant vinorelbine plus cisplatin regimen for NSCLC";
var content_f9_26_9646=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adjuvant vinorelbine plus cisplatin for resected early stage non-small cell lung cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: Every 28 days, for four cycles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Vinorelbine",
"        </strong>",
"       </td>",
"       <td>",
"        25 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in normal saline (NS) to a final concentration between 0.5 and 2 mg/mL and administer over 6 to 10 minutes into the side port of a free-flowing IV infusion.",
"       </td>",
"       <td>",
"        Days 1, 8, 15, and 22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cisplatin",
"        </strong>",
"       </td>",
"       <td>",
"        50 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL NS and administer over two hours. Do not administer with aluminum needles or sets.",
"       </td>",
"       <td>",
"        Days 1 and 8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on Prevention.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        HIGH: days 1 and 8; MINIMAL: days 15 and 22. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Vinorelbine is a vesicant and can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with hematopoietic growth factors is not recommended (incidence of febrile neutropenia is approximately 7 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for preexisting baseline liver or renal dysfunction:",
"        </strong>",
"        A lower starting dose of vinorelbine may be needed for patients with hepatic impairment. The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Such patients were excluded from the original trial",
"        <sup>",
"         [1]",
"        </sup>",
"        . Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Basic metabolic panel (creatinine and electrolytes) prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Liver function tests prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Treatment with vinorelbine should be delayed until ANC is greater than 1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        based on the manufacturer's guidelines. A dose reduction of 50 percent is recommended for patients with ANC 1000/mm",
"        <sup>",
"         3",
"        </sup>",
"        to 1500/mm",
"        <sup>",
"         3",
"        </sup>",
"        . If a patient's ANC is &lt;1000/mm",
"        <sup>",
"         3",
"        </sup>",
"        , the weekly dose of vinorelbine should be held and blood counts should be rechecked in one week. For patients who develop febrile neutropenia or who have had two consecutive weekly doses held, the following dose adjustments will apply for subsequent doses of vinorelbine. For ANC &ge;1500/mm",
"        <sup>",
"         3",
"        </sup>",
"        , use a 25 percent dose reduction. For ANC 1000/mm",
"        <sup>",
"         3",
"        </sup>",
"        to 1400/mm",
"        <sup>",
"         3",
"        </sup>",
"        , use a 62.5 percent dose reduction. If ANC remains &lt;1000/mm",
"        <sup>",
"         3",
"        </sup>",
"        , hold vinorelbine doses until count recovery and then follow above dosing guidelines",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurotoxicity:",
"        </strong>",
"        Neuropathy usually is seen with cumulative doses of cisplatin &gt;400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Nephrotoxicity:",
"        </strong>",
"        Hold cisplatin until serum creatinine &lt;1.5 mg/dL and/or blood urea nitrogen &lt;25 mg/dL. For grade &ge;2 nephrotoxicity during treatment (creatinine &gt;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &lt;60 mL/min.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hepatotoxicity:",
"        </strong>",
"        The FDA-approved package insert recommends dose reduction for patients who develop hyperbilirubinemia during treatment with vinorelbine:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"4\">",
"        - Serum bilirubin &le;2.0 mg/dL, give 100 percent of dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"4\">",
"        - Serum bilirubin 2.1 to 3.0 mg/dL, give 50 percent of dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"4\">",
"        - Serum bilirubin &gt;3.0 mg/dL, give 20 percent of dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count; ANC: absolute neutrophil count.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Winton T, et al. N Engl J Med 2005; 352:2589.",
"      </li>",
"      <li>",
"       Navelbine (vinorelbine) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 14, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_26_9646=[""].join("\n");
var outline_f9_26_9646=null;
var title_f9_26_9647="Lupus arthritis swan neck";
var content_f9_26_9647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F78325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F78325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lupus arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with long-standing lupus has developed subluxation at the MCP joints and swan neck deformities of her fingers. These deformities are reducible (probably being due to lax tendons) and x-rays reveal no erosions or cysts, both of which differentiate these findings from those in rheumatoid arthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter H Schur, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_26_9647=[""].join("\n");
var outline_f9_26_9647=null;
